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Rhinovirus (RV) is a small positive-stranded RNA virus of the Picornaviridae 
family. It contains a single-stranded positive-sense RNA genome of about 8 kb in length 
that is enclosed in a non-enveloped icosahedral capsid, which in turn consists of a 
densely packed arrangement of 60 protomers. Each protomer is comprised of four 
polypeptides: VP1, 2, 3, and 4 (1-2). VP1, 2, and 3 are located on the capsid surface, 
whereas VP4 is located on the internal side of the capsid.  
RV virion RNA is infectious and serves as both the genome RNA and viral 
messenger RNA (mRNA). The 5′ end of RV genome is covalently attached to a viral 
protein, VPg, instead of a methylated nucleotide cap structure, as in eukaryotic RNA. 
VPg is believed to be important for viral replication (3). A long untranslated region at the 
5′ end contains a cloverleaf-like internal ribosome entry site (IRES), which allows direct 
translation of viral protein (4). A shorter untranslated region at the 3′ end is important for 
negative-strand synthesis during replication.  
Sequencing of the human rhinovirus 14 genome reveals a single large open 
reading frame of 6536 nucleotides, starting at nucleotide 678 and ending 47 nucleotides 
from the 3′ end. The open reading frame encodes a single polypeptide that is divided into 
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functional viral proteins. Starting from the 5′ end, the single open reading frame is 
translated into a large polypeptide precursor that is divided into three regions: the P1 
region, which encodes the capsid proteins VP1, 2, 3, and 4; and the P2 and P3 regions, 
which encode the non-structural proteins 2APro, 2B, 2C, 3A, VPg, 3CPro and 3DPol. 
Facilitated by viral proteases 2A and 3C, the polypeptide precursor is cleaved and 
processed into the mature viral proteins by a sequence of proteolytic cleavages. Note that 
some viral proteases may also interact with the host cell proteins to promote viral 
replication (5-6). For example, 2Apro is responsible for the cleavage of the eukaryotic 
translation initiation factor 4G (eIF4G), which leads to the prevention of host cell protein 
synthesis (7). 
There are over 100 known RV serotypes, and cross-protection between the 
serotypes is negligible, preventing both an efficient immune response and development of 
a cost-effective vaccination strategy. At least 99 RV serotypes that affect humans have 
been sequenced (8). The major group serotypes (~90%; e.g., RV14, 16, and 39) bind to 
the intercellular adhesion molecule (ICAM)-1 (9). The minor group serotypes (e.g., 
RV1B) bind to low-density lipoprotein family receptors (10). A third group of previously 
unrecognized RV serotypes has been identified and shown to cause respiratory illness, 
particularly in infants (11-12). However, these serotypes have not been cultured. A recent 
study reported that VP4 is highly conserved among many RV serotypes, suggesting 
potential for  a pan-serotype RV vaccine (13). 
Upon infection, RV binds to its cell surface receptor and is endocytosed. Receptor 
binding, along with endosomal acidification, triggers the uncoating and subsequent 
release of viral RNA into the cytosol (14-16). Using the positive-sense RNA genome as 
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the template, viral RNA-dependent RNA polymerase 3D then forms the corresponding 
negative strand, which serves as a template for synthesizing a new positive-strand RNA. 
It has been shown that the RV genome can arrive in the cytosol 10 min post-infection 
from late endosomal compartments (17).  Viral replication may occur as early as 3 h after 
infection.  Finally, at an optimal temperature range of 33ºC–35ºC (the temperature of 
human nasal passages), assembled mature virions are released from the cell 8–10 h after 
infection. This temperature requirement was originally thought to exclude RV as a lower 
respiratory tract pathogen. However, there is increasing evidence that RV is able to 
replicate in the lower respiratory tract. RV RNA has been detected in lower airway cells 
from the bronchoalveolar lavage (BAL) of infected subjects (18-19), and RV capsid 
protein was observed in bronchial biopsies after viral inoculation (20). RV RNA has also 
been detected in bronchial biopsies of asthmatic subjects long after their exacerbation 
symptoms have cleared (21). These studies suggest that RV may infect the lower airways 





 The innate immune system is no longer considered to be a primitive and weak 
first line of protection, but rather, it is a highly active antiviral defense that has potential 
for therapeutic manipulation. The IFN family of cytokines is one of the key components 
of  antiviral innate immunity, and the induction of IFNs is the first line of defense against 
viral infection (22).  
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 Three types of IFN have been identified and classified according to the receptor 
complex through which they signal. Type I IFNs, which in humans mainly comprise 13 
IFN-α subtypes and IFN-β, engage the ubiquitously expressed IFNAR (IFN-α receptor) 
complex that is comprised of IFNAR1 and IFNAR2. Type I IFNs induce hundreds of 
genes that promote a robust antiviral state against viral infection. The importance of the 
IFN signaling network is illustrated by the extreme susceptibility to viral infection of 
mice that lack IFN receptors (23-24). IFNAR-deficient mice have increased susceptibility 
to numerous viruses (25), and humans with genetic defects in components of the IFNAR 
signaling pathway die of viral diseases (26-27). The type II IFN response is comprised of 
the single IFN-γ gene product that binds the IFN-γ receptor complex and mediates a 
broad immune response to pathogens other than viruses. The most recently described are 
the type III IFNs, which include three IFN-λ gene products that signal through receptors 
containing IFNLR1 (also known as IL-28Ra) and IL-10R2 (also known as IL-10Rb). 
Type III IFNs are structurally and genetically distinct from type I IFNs and act through a 
distinct receptor system. However, with regard to mechanisms of induction, signal 
transduction, and biological activities, they are surprisingly similar (28).  
 
Interferon-stimulated Genes (ISGs) 
After binding to their ligands, type I IFN receptors activate the downstream Jak-
Stat pathway by associating with the Janus protein tyrosine kinases (Jak PTKs) Tyk2 and 
Jak1 via their intracellular domains (29). The activation of these Jak PTKs results in the 
phosphorylation of their downstream transcription factors Stat1 and Stat2. Tyrosine 
phosphorylation of stat 1 and 2 leads to the formation of the transcriptional activator 
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complex IFN-stimulated gene factor 3 (ISGF3), which then translocates to the nucleus 
and binds to the IFN-stimulated regulatory element (ISRE), resulting in the 
transcriptional induction of a number of ISGs which in turn mediate the antiviral 
response (30).  
 The binding of type I IFNs to the IFNAR complex initiates a signaling cascade 
that leads to the induction of more than 300 ISGs (31), such as ISG15, MxGTPase, 2′,5′ 
oligoadenylate synthetase (OAS), RNaseL, and protein kinase R (PKR). ISG15, a 
ubiquitin homologue, can promote antiviral signaling by attaching to effector proteins 
such as RIG-I, a process called ISGylation (32). The expression of MxGTPase is induced 
through an ISRE in the gene promoter after stimulation with type I IFNs. The MxGTPase 
family proteins degrade newly synthesized viral components at early time points (33). 
OAS accumulates in the cell cytoplasm as an inactive monomer. After the formation of 
viral double-stranded RNA (dsRNA), OAS forms a tetramer that synthesizes 2′,5′-
oligoadenylates. Oligoadenylates, in turn, activate RNaseL. Activated RNaseL forms a 
homodimer that degrades viral single-stranded RNA (ssRNA) (34). In this manner, OAS, 
in combination with RNaseL, constitutes an antiviral RNA decay pathway. PKR is a 
protein kinase that is constitutively expressed in all tissues at a basal level. In response to 
environmental stresses, PKR inhibits protein synthesis by phosphorylation of eukaryotic 
translation initiation factor-2α. PKR is directly activated by dsRNA and other ligands 
such as ceramide (35). Infection of airway epithelium by both major and minor RV 
groups has been shown to activate antiviral IFN pathways, and the disruption of these 




Interferon-related transcription factors  
 Upon viral infection, IFN induction is transcriptionally regulated by the IFN-
regulatory factor (IRF) family, as well as other transcription factors, such as NF-κB and 
ATF2/c-Jun (37-38). The transcription factors bind to specific motifs in the IFN promoter 
(39-40). The homologous proteins IRF3 and IRF7 are activated in response to IFN and 
viral stimulation (41). NF-κB and ATF2/c-Jun are activated in response to various stimuli, 
including viral binding, leading to the expression of genes relevant to inflammation (42). 
These transcription factors form a transcription regulatory unit called an enhanceosome 
and cooperatively activate the transcription of IFN genes (43).  
Among the nine IRF family members (IRF1-9), an essential role for IRF3 and 
IRF7 in the activation of IFN-α/β was demonstrated by an analysis of IRF3 and IRF7 
knockout mice (41, 44). IRF3, which is constitutively expressed in most cell types, 
resides in the cytosol in a latent form. It has multiple serine and threonine 
phosphorylation sites in its C-terminal region (45-46). Upon either viral infection or IFN 
stimulation, IRF3 is transcriptionally upregulated and undergoes phosphorylation, 
dimerization, and nuclear translocation (47-49). IRF3 is phosphorylated by two non-
canonical IκB kinases: TANK-binding kinase 1(TBK1) and IκB kinase ε/ι (IKKε/ι), 
which are structurally related and possibly redundant in function (38, 50). IRF7 
phosphorylation is similar; however, IRF7 expression is differentially regulated. In 
fibroblasts and conventional dendritic cells (cDCs), IRF7 is expressed at low levels and 
can be induced by the trace amount of IFN produced (51-52). Two models of IRF3 
activation and dimerization have been proposed: the phosphorylation-induced 
dimerization model and the autoinhibitory model (53-54). Regardless of the model, the 
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dimeric form of IRF3 (either a homodimer or a heterodimer with IRF7) then translocates 
to the nucleus, forms a complex with the coactivators CBP and/or p300, and binds to its 
target DNA sequence in type I IFN genes, as well as in certain cytokine and chemokine 
genes, to regulate their expression. Initially, a small amount of type I IFN is produced and 
secreted. It then stimulates the type I IFN receptor in an autocrine and a paracrine fashion, 
leading to the activation of the IFN pathway and the transcription of the IRF7 gene. The 
activation of newly synthesized IRF7 results in further transcription of type I IFN genes; 
thus, a massive IFN production can be achieved through this positive feedback 
mechanism (52, 55).  
In contrast, IFN-β expression does not strictly require IRF3 and IRF7. The 
expression of IFNs is usually regulated by a number of transcription factors that form an 
enhanceosome (43, 56-58). Daffis and colleagues observed that the IFN-β response in the 
macrophages and dendritic cells of mice lacking both IRF3 and IRF7 was minimally 
diminished after West Nile virus (WNV) infection (59). This suggests that IFN-β 
regulation after WNV infection does not always require full occupancy of the IFN-β 
enhanceosome by canonical constituent transcription factors. Therefore, the participation 
of various transcription factors in the enhanceosome and their spatial location relative to 
the promoter region determines the final outcome of viral infection, i.e., the pattern of 
cytokine expression (60-61).  
NF-κB, which consists of p65 (RelA) and p50, is involved in the expression of 
type I IFNs and proinflammatory cytokines. In unstimulated cells, the p65:p50 
heterodimer is retained in the cytoplasm through its binding with the NF-κB inhibitor 
(IκB) (61-62). In response to viral infection, IκB is phosphorylated by the IκB kinase 
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(IKK) complex, comprised of IKKα, IKKβ, and the regulatory component IKKγ 
(NEMO). It is then ubiquitinated and degraded by the proteosome, which leads to the 
release of the p65:p50 NF-κB dimer into the nucleus.  
 
Pattern Recognition Receptors 
 The discovery of pattern recognition receptors (PRRs) revolutionized the 
understanding of innate immunity, explaining why and how multiple and diverse 
infectious agents are recognized by a limited number of innate immune receptors that 
trigger antimicrobial responses (63). Studies have shown that viral induction of type I 
IFNs is mediated mainly by the activation of PRRs including Toll-like receptors (TLRs) 
(64-65), retinoic acid inducible gene-I (RIG-I), and melanoma differentiation-associated 
gene 5 (MDA5) (66-67). These germline-encoded PRRs are responsible for sensing the 
presence of microorganisms by recognizing structures conserved among microbial 
species, namely pathogen-associated molecular patterns (PAMPs), as well as endogenous 
molecules released from damaged cells, termed damage-associated molecular patterns 
(DAMPs). Several distinct family members are responsible for the detection of different 
components of pathogens (68-73). A summary of PRRs and their respective ligands is 
provided in Table 1.  
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Table 1. Pattern recognition receptors (PRRs) and their ligands 
PRRs Location Ligands 
TLR   
TLR1 Plasma membrane Triacyl lipoprotein 
TLR2 Plasma membrane Peptidoglycan 
TLR3  Endosome dsRNA 
TLR4 Plasma membrane LPS, viral glycoproteins 
TLR5 Plasma membrane Flagellin 
TLR6 Plasma membrane Diacyl lipoprotein 
TLR7/8 Endosome ssRNA 
TLR9 Endosome unmethylated CpG-DNA 
RLR   
RIG-I Cytoplasm Short dsRNA, 5'-ppp dsRNA 
MDA5 Cytoplasm Long dsRNA 
LGP2  Cytoplasm Unknown 
NLR   
NOD1 Cytoplasm Bacteria peptidoglycan 
NOD2 Cytoplasm Bacteria peptidoglycan 
NALP1 Cytoplasm DAMPs 
NALP2 Cytoplasm DAMPs 
NALP3 Cytoplasm DAMPs, bacteria & virus RNA 
DNA sensor   
DAI Cytoplasm dsDNA (B-form) 









There are two general principles applied to PRRs that induce type I IFNs: 1) all 
PRRs that activate the type I IFN response detect microbial nucleic acids due to a lack of 
conserved features in other viral components; 2) all PRRs trigger the type I IFN response 
from an intracellular location (22). One possible exception is TLR4, which is believed to 
be located on the cell surface. TLR4 detects lipopolysaccharides (LPS) and viral 
glycoprotein derived from gram-negative bacteria and activates type I IFNs in cDCs and 
macrophages through a signaling pathway that uses TIR domain-containing adapter-
inducing interferon-β (TRIF) as an adaptor protein (74-75). However, it has been 
proposed that TLR4-mediated IFN production occurs only after TLR4 sequentially 
translocates to early endosomes and activates a set of adaptors after initially signaling at 
the plasma membrane via a different set of adaptors (76). Similarly, TLR2 is also 
believed to signal from the plasma membrane. It recognizes cell wall components, such 
as peptidoglycans, leading to the production of inflammatory cytokines, but not IFNs (77-
78). However, when activated by vaccinia virus, TLR2 can also induce type I IFNs after 
endocytosis, but only in inflammatory monocytes (79). Considered together, these 
observations challenge the general principle that only nucleic acids can trigger the IFN 
response, but support the idea that all PRRs that trigger the type I IFN response do so 
from an intracellular location. Similar to virus-induced responses, a potent type I IFN 
response can be induced by intracellular bacterial infections through PRRs (80-82). 
However, whether this IFN induction is beneficial to the host is not clear (83-85).  
The most common nucleic acid ligands stem from the genomes of infecting 
viruses or from the intermediates involved in viral replication. The receptors that sense 
nucleic acids fall into two categories. The first class of PRRs, specifically TLRs, detects 
11 
 
viral nucleic acids in endosomes and in specialized cell types (22). The second class of 
PRRs is expressed ubiquitously; they are localized to the cytosol where they detect viral 
nucleic acids produced during infection.  
 
Toll-like receptors 
TLRs, numbered 1-11, are a family of single-transmembrane proteins expressed 
predominantly on key sentinel cells of the innate immune system, such as macrophages 
and DCs (86). All TLRs have an extracellular leucine-rich repeat (LRR) motif for the 
recognition of specific PAMPs and a cytoplasmic Toll-interleukin-1 receptor (TIR) 
domain to transmit intracellular responses through the recruitment of TIR-containing 
adaptors (87). These adaptors, including MyD88, TRIF (TICAM-1), TRAM, and TIRAP, 
mediate cellular events that lead to the induction of inflammatory genes (88). Among the 
TLR family members, TLR1, 2, 4, 5, and 6 are expressed on the cell surface and are 
responsible for the detection of extracellular PAMPs, such as bacterial and fungal cell 
wall components; whereas TLR3, 7, 8, and 9 recognize viral nucleic acid ligands in 
intracellular compartments, such as endosomes (89-94). This intracellular localization is 
thought to enable the discrimination between self and non-self nucleic acids: relocating 
TLR9 to the cell surface abolishes its ability to respond to virus-encapsulated DNA but 
enables recognition of self-derived genomic DNA in the extracellular milieu (95). The 
endosomal TLRs usually require endoplasmic reticulum protein UNC-93B to deliver 
them to the endosomal compartment (96).  
TLR3 recognizes viral dsRNA, which is found in the genome of dsRNA viruses 
or in replication or transcription intermediates of ssRNA viruses or DNA viruses. The 
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expression of TLR3 is predominantly observed in the intracellular compartments of cDCs 
and macrophages; some fibroblasts also express TLR3 on their cell surface (68). After 
ligand binding, TLR3 is activated and binds to its adaptor protein TRIF via a TIR-TIR 
homotypic interaction, which then recruits a set of signaling molecules, including tumor 
necrosis factor (TNF) receptor-associated factors (TRAF)3, TRAF6, receptor interacting 
protein 1 (RIP1), and transforming growth factor-α-activated kinase 1 (TAK1), leading to 
the activation of NF-κB, IRF3, and IRF7, and eventually, the engagement of the antiviral 
IFN pathway (97-98).  
 
Cytoplasmic PRRs 
Numerous observations suggest that host cells express additional receptors that 
detect actively replicating viruses in the cytoplasm. Recently, RIG-I and MDA5 have 
been characterized as cytoplasmic dsRNA receptors that play a vital role in the antiviral 
innate immune response. RIG-I, whose expression is induced by retinoic acid, IFN, and 
viral infection, is a member of the DExD/H box RNA helicases (99). 
Human RIG-I encodes for a protein of 925 amino acids. Its N-terminal region is 
characterized by the presence of two caspase recruitment domains (CARD), and its C-
terminal helicase domain harbors potential ATP-dependent RNA helicase activity. Over-
expression of the N-terminal twin CARD domains is sufficient to activate NF-κB and 
IRF3 in the absence of a viral challenge, whereas the full length of RIG-I is activated 
only in the presence of dsRNA. Thus, the binding of dsRNA to the RNA helicase domain 
of RIG-I likely induces a conformational change that exposes the N-terminal CARD 
domains to initiate the recruitment of downstream signaling proteins (100). The 
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functional significance of RIG-I in antiviral immunity was first shown by RNA 
interference (RNAi) studies and subsequently confirmed by mouse knockout studies 
(101-102). RNAi of RIG-I in a mouse fibroblast cell line inhibited not only IRF3 
activation but also subsequent induction of type I IFNs in response to RNA viruses (the 
specificity of RIG-I for particular viruses is discussed below). The embryos of RIG-I 
knockout mice displayed severe liver degeneration. However, studies also showed that 
pretreatment of lung fibroblasts with IFN-β increased the resistance of RIG-I-deficient 
fibroblasts to vesicular stomatitis virus (VSV), indicating that RIG-I is required for the 
induction of IFN-β,  but RIG-I deficiency does not necessarily affect the downstream 
IFN-β amplification signaling (101).  
MDA5 is structurally related to RIG-I, as it contains two N-terminal CARD-like 
domains and a single C-terminal helicase domain (103-104). Like RIG-I, MDA5 is also 
an IFN-inducible gene. Overexpression of MDA5 leads to enhanced antiviral responses 
to infection with Newcastle disease virus (NDV), VSV, or encephalomyocarditis virus 
(EMCV), as evidenced by increased expression of type I IFNs; whereas knockdown of 
MDA5 blocks NDV-induced activation of type I IFN promoters (67).  
RIG-I and MDA5 both use their CARD domains to signal downstream events, 
which suggests they may signal through a common CARD adaptor molecule. Such an 
adaptor was identified on the mitochondria membrane and named IFN-β promoter 
stimulator-1 (IPS-1, also called MAVS, Cardif, or VISA) (105-108). It has been 
confirmed that both RIG-I and MDA5 signaling converge at IPS-1 before activating 
downstream transcription factors IRF3 and NF-κB (109). Interestingly, when IPS-1 is 
released from the mitochondria to the cytoplasm or when it is targeted to another 
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organelle such as the endoplasmic reticulum, it no longer mediates downstream IRF and 
NF-κB activation, suggesting a role for mitochondria in antiviral immunity (106). The 










Even though both the cytoplasmic RIG-I/MDA-5 and endosomal TLR pathways 
can activate IFN signaling, they are not functionally redundant. Mice deficient in IPS-1 
are highly susceptible to infection despite an intact TLR system (109-110). Kato and 
colleages clarified the relative contribution of each in antiviral defense by showing their 
cell type-specific requirements (102). TLRs are activated when they recognize nucleic 
acids within the endosomal compartments of plasmacytoid DCs (pDCs), whereas RIG-I 
defends the host against viral infections, including NDV, VSV, and Sendai virus (SeV), 
within the cytoplasm of mouse embryonic fibroblasts (MEFs) and cDCs. Hence, cell type 
specificity may reflect the differential ability of infected cells to recognize viral-derived 
nucleic acids in different compartments and to preferentially trigger TLR- or RIG-I-
dependent responses.  
RIG-I and MDA5 each have unique specificity in ligand binding. RIG-I and 
MDA5 knockout mice show impaired antiviral responses against different viruses. RIG-I, 
but not MDA5, mounts antiviral responses against the positive-strand ssRNA Japanese 
encephalitis virus, and against a set of negative-strand ssRNA viruses including NDV, 
VSV, SeV and influenza virus. In contrast, MDA5 detects the presence of EMCV, a 
member of the picornavirus family (102, 111). RIG-I recognizes relatively short dsRNA 
(up to 1 kb), especially dsRNA with a 5′ triphosphate, which greatly enhances type I IFN-
inducing activity (112-113). MDA5, in contrast, recognizes long dsRNA (more than 2 kb) 
such as poly I:C. Shortening the length of poly I:C by a dsRNA-specific nuclease 
converts the poly I:C from an MDA5 ligand to a RIG-I ligand (69). Therefore, 
recognition is specific at the level of both cell type and pathogen.  The receptors required 
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to recognize RV dsRNA and to trigger the downstream immune response in airway 
epithelial cells have not been identified. 
 
Animal models of RV infection   
Species differences in ICAM-1 represent the main challenge in developing an 
animal model of a human major group RV infection. Recently, we (114) and others (115) 
showed that minor group serotype RV1B, which binds proteins of the low-density 
lipoprotein receptor family, infects C57BL/6 and Balb/c mice, thereby providing an 
animal model to study RV-induced airway inflammation. We reported evidence of human 
RV1B replication in mouse lungs as follows: 1) the presence of negative-strand viral 
RNA in the lungs of inoculated mice, 2) the transmissibility of RV infection from the 
lung homogenates of inoculated mice to cultured HeLa cells, and 3) the induction of a 
robust lung IFN response (114).  Replication-deficient UV-irradiated virus elicited none 
of these effects. RV infection also caused a moderate increase in airway resistance to 
methacholine, suggesting a role for RV-induced airway inflammation in airway hyper-
reactivity.  
The airway response to the major group virus RV16 was recently studied using a 
transgenic mouse expressing humanized ICAM-1 (115). The effects induced by RV16 
were indistinguishable from those induced by RV1B. Studies indicate that major and 
minor group viruses induce nearly identical patterns of gene expression in cultured 
airway epithelial cells (36). Furthermore, recent analysis of all known HRV genomes has 
revealed that HRV1 and HRV16 are highly homologous and respond similarly to small-
molecule antiviral compounds (116). Thus, the distinction between at least some major 
17 
 
and minor group strains may not be clinically relevant. Therefore, we believe that mouse 
models of human RV1B infection hold promise for the study of RV-induced 
exacerbations of chronic airway diseases, such as asthma.   
 
RV-induced airway inflammation 
Another main component of the innate immune response, besides the IFN 
response, is the inflammatory response. The expression of cytokines from a small number 
of RV-infected epithelial cells can orchestrate the proliferation, chemotaxis, and 
attraction of peripheral inflammatory cells to the infection site, initiating the 
inflammatory response. RV infection of primary epithelial cells and epithelial cell lines is 
accompanied by the release of inflammatory mediators in vivo and in vitro; in particular, 
the pro-inflammatory cytokines, TNF, CXCL8/IL-8, IL-6, CCL5/RANTES, CCL2/MCP-
1, and CXCL10/IP-10 (42, 117-118). Consequently, common cold symptoms are now 
considered to result from an inflammatory cytokine disease of the host in response to the 
virus and not from the virus itself (119).  
Attracted by chemokines, inflammatory leukocytes, granulocytes, DCs, and 
monocytes migrate to the site of infection (120). Neutrophil infiltration, in particular, into 
the submucosa and epithelium during the common cold is likely caused by the secretion 
of IL-8, which is a potent chemoattractant and mediator of neutrophils (121). The 
increased presence of neutrophils suggests that they are the predominant inflammatory 
cells during virus-induced asthma exacerbations, whereas eosinophils are responsible for 
allergen-provoked asthma (122). However, it has been reported that eosinophils are 
increased in biopsies of bronchial epithelium taken from healthy and asthmatic persons 
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after experimental RV infection (123). These observations suggest that both neutrophils 
and eosinophils are necessary for RV-induced asthma exacerbation.  
 
The role of RV-induced IFN responses in asthma exacerbation 
Viral respiratory tract infections are responsible for up to 85% of asthma 
exacerbations (124-125). RV is the main virus associated with asthma exacerbations, 
responsible for up to 80% of virus-induced asthma exacerbations (126). Corne and 
colleagues were the first to suggest there may be inherent differences in the way 
asthmatic and non-asthmatic individuals respond to respiratory viral infections, given that 
asthmatic individuals have more severe symptom scores and a greater decrease in lung 
function compared to non-asthmatic individuals, despite similar rates of acute viral 
infection (127). A subsequent study found that asthmatic bronchial epithelial cells 
produced less type I IFN-β, exhibited higher levels of RV replication, but similar levels 
of pro-inflammatory cytokine induction (128), suggesting that the differences between 
asthmatic and non-asthmatic individuals are more specific to antiviral IFNs. Another 
group showed similar phenotypes using a human experimental infection model of adults 
with mild-to-moderate asthma (129). These studies collectively established a striking link 
between asthma and a deficiency in the innate immune response, and formed a new 
paradigm for the role of innate immune responses to viruses in asthma. However, the 
mechanisms behind this paradigm are provoking vigorous debate. First, several groups 
have failed to confirm a deficient IFN response in asthmatic airway epithelial cells. 
Indeed, one group found elevated type III IFN mRNA in the sputum of children and 
adults with asthma (130). Clearly, confirmation of a deficiency in IFN responses in 
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asthmatics requires further investigation. Second, and of equal significance, it remains 
unclear whether this deficiency in IFN responses, if present, is causative of asthma or is 
merely a consequence of asthma. More studies are required to answer these important 
questions.  
 Our studies aim to examine the mechanisms of the RV-induced innate immune 
response both in vivo and in vitro, using a cultured airway epithelial cell line, primary 
bronchial epithelial cells, and knockout mice. Further, using an allergic airway disease 
mouse model established previously in the laboratory, we aim to determine the role of the 
IFN response in RV-induced asthma exacerbation. The results of this program of study 
will elucidate the mechanisms underlying the innate immune response to RV infection 
and the contribution of RV infection to asthma exacerbation. The overall goal will be 
resolved by the following specific aims:  
1. To determine the contribution of RIG-I, MDA5, and TLR3 in RV-induced IFN 
responses in vitro (Chapter 2); 
2. To determine the contribution of MDA5 and TLR3 in RV-induced innate immune 
responses in naïve mice (Chapter 3); 
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Role of double-stranded RNA pattern recognition receptors in 
rhinovirus-induced airway epithelial cell responses 
 
Summary 
 Rhinovirus (RV), a single-stranded RNA virus of the picornavirus family, is a 
major cause of the common cold as well as asthma and chronic obstructive pulmonary 
disease (COPD) exacerbations. Viral double-stranded RNA produced during replication 
may be recognized by the host pattern recognition receptors Toll-like receptor (TLR)-3, 
retinoic acid inducible gene (RIG)-I and melanoma-differentiation-associated gene (MDA)-
5.  No study has yet identified the receptor required for sensing RV double-stranded (ds)-
RNA. To examine this, BEAS-2B human bronchial epithelial cells were infected with 
intact RV-1B or replication-deficient UV-irradiated virus, and interferon (IFN) and IFN-
stimulated gene expression determined by quantitative PCR.  The separate requirements of 
RIG-I, MDA5 and IFN response factor (IRF)-3 were determined using their respective 
siRNAs. The requirement of TLR3 was determined using siRNA against the TLR3 adaptor 
molecule TRIF. Intact RV-1B, but not UV-irradiated RV, induced IRF3 phosphorylation 




MDA5, IP-10/CXCL10, IL-8/CXCL8 and GM-CSF. siRNA against IRF3, MDA5 and 
TRIF, but not RIG-I, decreased RV1B-induced expression of IFN-β, IFN- λ1, IFN-λ2/3, 
IRF7, RIG-I, MDA5 and IP-10/CXCL10, but had no effect on IL-8/CXCL8 and GM-CSF.  
siRNAs against MDA5 and TRIF also reduced IRF3 dimerization. Finally, in primary cells, 
transfection with MDA5 siRNA significantly reduced IFN expression, as it did in BEAS-
2B cells. These results suggest that TLR3 and MDA5, but not RIG-I, are required for 
maximal sensing of RV dsRNA, and that TLR3 and MDA5 signal through a common 
downstream signaling intermediate, IRF3.  
 
Introduction 
Viral infections, most commonly caused by rhinovirus (RV), are a frequent cause of 
asthma  and chronic obstructive pulmonary disease exacerbations (1). RV is a non-
enveloped, positive, single-stranded RNA virus from the Picornaviridae family. RV is 
internalized by receptor-mediated endocytosis and undergoes a conformational change at 
endosome low pH, leading to insertion of viral RNA into the cytosol. After entry, 
replication occurs entirely in the cytoplasm, where single-stranded RNA forms a double-
stranded (ds)-RNA intermediate, the main form of viral RNA genome inside the cell.  
dsRNA produced during viral infection represents an important stimulus of the 
host innate immune response.  It is recognized and engaged by three pattern recognition 
receptors. Toll-like receptor (TLR)-3 is localized to the endosomal and plasma 
membranes. TLR3 senses dsRNA released from dying cells and signals through its 




The cytoplasmic proteins retinoic acid-inducible gene (RIG)-I and melanoma 
differentiation-associated gene (MDA)-5 have recently been identified as intracellular 
receptors for viral dsRNA (3, 4). RIG-I and MDA5 are homologous cytoplasmic 
helicases containing two amino-terminal caspase activation and recruitment domains 
(CARDS) and a carboxy-terminal DExD/H-Box RNA helicase domain. They bind to 
dsRNA through the helicase domain and signal through CARD domains to a common 
adaptor molecule, interferon-beta promoter stimulator (IPS)-1 (also called VISA) (5, 6).  
Engagement of TLR3, RIG-I or MDA5 initiates signaling through two protein kinase 
complexes, TANK-binding kinase (TBK1)/IκB kinase-ε (IKKε) and IKKα/IKKβ, 
leading to activation of interferon regulated factor (IRF)-3 and nuclear factor (NF)-κB, 
respectively (7).  Transcription factor activation, in turn, induces expression of IFNs and 
pro-inflammatory cytokines. 
Although all three receptors can recognize viral dsRNA, they appear to be 
specialized in their recognition of particular viruses. RIG-I and TLR3 are required for 
respiratory syncytial virus (RSV)-induced expression of IFN-β and IP-10 in airway 
epithelial cells (8). RIG-I-deficient mice fail to produce type I IFNs in response to the 
negative-sense single-stranded RNA (ssRNA) viruses Newcastle disease virus, Sendai 
virus, vesicular stomatitis virus and influenza virus, and to the positive-sense ssRNA 
Japanese encephalitis virus, whereas MDA5-deficient mice fail to detect 
encephalomyocarditis (EMCV), a positive-sense ssRNA picornavirus (9). The 
engagement of PRRs is also cell-type specific: for example, while MDA5 is essential for 
induction of type I IFNs after infection with EMCV in fibroblasts and conventional 




 Little is known about the contributions of the various pattern recognition 
receptors to RV-induced responses in bronchial epithelial cells. Primary human bronchial 
epithelial cells express TLR3, and the TLR3 ligand polyI:C elicits a strong pro-
inflammatory response in these cells (10, 11).  In 16HBE14o- human bronchial epithelial 
cells, TLR3 is primarily localized in the endosomes, not on the cell surface (12). TLR3 is 
partially required for RV39-induced IL-8 expression in 16HBE14o- cells (12) and 
RV1A-induced MUC5AC expression in NCI-H292 mucoepidermoid carcinoma cells 
(13).  However, the requirement of either RIG-I or MDA5 for RV-induced responses has 
not yet been tested.  In the present study, we found that MDA5 and TLR3, but not RIG-I, 
are required for RV-induced IFN responses in human airway epithelial cells.    
 
Materials and Methods 
Cell culture 
BEAS-2B human bronchial epithelial cells, a SV-40-transformed airway 
bronchial epithelial cell line, were purchased from ATCC (Manassas, VA). Cells were 
grown on collagen-coated (5 μg/cm2) plates in Bronchial Epithelial Growth Medium 
(BEGM, Lonza, Conshohocken, PA) containing epidermal growth factor (25 ng/ml), 
bovine pituitary extract (65 ng/ml), all-trans retinoic acid (5 x 10-8 M), hydrocortisone 
(0.5 μg/ml), insulin (5 μg/ml), transferrin (10 μg/ml), epinephrine (0.5μg/ml), 
triiodothyronine (6.5 ng/ml), gentamycin (50 μg/ml) and amphotericin (50 μg/ml).  
 Primary tracheal epithelial cells were all isolated from the tracheas of lung 




80-100% confluence in BEGM containing epidermal growth factor (25 ng/ml), bovine 
pituitary extract (130 ng/ml), all-trans retinoic acid (5 x 10-8M) and bovine serum 
albumin (1.5 μg/ml). 
RV infection   
RV1B and RV39 were obtained from ATTC. Viral stocks were generated by 
incubating HeLa cells with RV in serum-free medium until 80% of the cells were 
cytopathic. Viral stocks were concentrated, partially purified and titered as previously 
described (14, 15).  RV1B was irradiated with UV light at 100 μJ/cm2 for 10 min on ice, 
using a CL-1000 crosslinker (UVP, Upland, CA). 
Quantitative real-time PCR 
 Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA), then 
transcibed to first-strand cDNA using Taqman Reverse Transcription Reagents (Applied 
Biosystems, Foster City, CA). First-strand cDNA is then used to quantify the expression 
of IFN-α, IFN-β, IFN-λ1, λ2/3, IRF-7, IP-10/CXCL-10, IL-8/CXCL8 and GM-CSF 
mRNA levels by quantitative real-time PCR (qPCR) using specific primers and probes.  
Measurement of cytokine protein levels 
 BEAS-2B cells were grown to 80% confluence and infected with RV1B or 
medium alone for 1 h. Inoculum was then replaced BEGM. Twenty-four h later, 
supernatant was collected for the measurement of IFN-λ1, IP-10/CXCL-10 and IL-
8/CXCL-8 protein by enzyme-linked immunosorbent assay (ELISA, R&D Systems, 





 Cells were lysed with RIPA buffer (50 mM Tris, pH7.4; 150 mM NaCl; 5 mM 
EDTA; 50 mM NaF; 1% NP-40; 10% glycerol). 30 μg of protein lysate was loaded in 
each well. Lysates were resolved by SDS-PAGE. Proteins were transferred to 
nitrocellulose or PVDF membrane.  Membranes were blocked in 5% milk for 1 h at room 
temperature and probed with either mouse anti-RIG-I (Alexis Biochemicals, Plymouth 
Meeting, PA), goat anti-MDA5 (Santa Cruz Biotechnology, Santa Cruz, CA), rabbit anti-
IRF3 (IBL America, Minneapolis, MN), rabbit anti-TRIF (Cell Signaling, Danvers, MA) 
or rabbit anti-IRF7 (Abcam, Cambridge, MA). Antibody binding was detected with a 
peroxidase-conjugated anti-mouse, anti-rabbit or anti-goat IgG and chemiluminescence.  
Native PAGE to determine IRF3 dimerization 
BEAS-2B cells were lysed with native PAGE sample prep kit (Invitrogen, 
Carlsbad, CA).  Native PAGE was performed using 10% Ready Gel (Bio-rad, Hercules, 
CA), as described (16).  The gel was pre-run with 25 mM Tris and 192 mM glycine, pH 
8.4, with and without 1% deoxycholate in the cathode and anode chamber, respectively, 
for 30 min at 40 mA. Samples in the native sample buffer (10 μg protein, 62.5mM Tris-
Cl, pH 6.8, and 15% glycerol) were applied to the gel and electrophoresed for 60min at 
25 mA. Immunoblotting of IRF3 was performed as described above.  
 
siRNA knockdown of RIG-I, MDA5, IRF3 and TRIF.   
19-bp duplex of targeting siRNA or non-targeting siRNA (Dharmacon, Lafayette, 
CO) was transfected into subconfluent BEAS-2B cells while cell seeding using 




containing equal parts of the following antisense sequences was used to knockdown RIG-
I: 1, 5'- GCACAGAAGUGUAUAUUGG-3'; 2, 5'- CCACAACACUAGUAAACAA-3'; 3, 
5'- CGGAUUAGCGACAAAUUUA-3'; 4, 5'-UCGAUGAGAUUGAGCAAGA-3'. The 
non-targeting siRNA sequence was 5'-CGAACUCACUGGUCUGACCdtdt-3'(sense), 5’-
GGUCAGACCAGUGAGUUCG-dtdt-3’(antisense). For knockdown of MDA5, a pool of 
the following sequences was used: 1, 5’-GAAUAACCCAUCACUAAUA -3’; 2, 5’- 
GCACGAGGAAUAAUCUUUA -3’; 3, 5’- UGACACAAUUCGAAUGAUA -3’; 4, 5’-
CAAUGAGGCCCUACAAAUU’-3’. For knockdown of IRF3, a pool of the following 
sequences was used: 1, 5’-CGAGGCCACUGGUGCAUAU-3’; 2, 5’-
CCAGACACCUCUCCGGACA-3’; 3, 5’-GGAGUGAUGAGCUACGUGA-3’, 4, 5’-
AGACAUUCUGGAUGAGUUA-3’. For knockdown of TRIF, a pool of the following 
sequences was used: 1, 5’-GGAGCCACAUGUCAUUUGG-3’; 2, 5’-
CCAUAGACCACUCAGCUUU-3’; 3, 5’-GGACGAACACUCCCAGAUC-3’; 4, 5’-
CCACUGGCCUCCCUGAUAC-3’. The next morning, cells were incubated in fresh 
BEGM containing for 24 h. Finally, cells were treated with the relevant stimulus in 
BEGM medium for one day prior to harvest.  
Data analysis 
 SigmaStat computing software (SPSS, Chicago, IL) was used for data analysis.  
Data are represented as mean±SEM. Normality was tested using the Kolmogorov-
Smirnov test.  Statistical significance was assessed by either one-way analysis of variance 
(ANOVA) or the Kruskal-Wallis one-way ANOVA based on ranks, whenever 
appropriate. Differences identified by ANOVA were pinpointed by the Student Newman-





RV1B-induced IFN expression in BEAS-2B human bronchial epithelial cells 
 To test whether RV induces an IFN response in human bronchial epithelial cells, 
BEAS-2B cells were infected with intact RV1B or UV-irradiated RV-1B for 1 h at 33ºC. 
Cellular total RNA was extracted from lysates to measure the gene expression at 1, 8, 18, 
24, 48 and 72 h post-infection by quantitative PCR. Compared with replication-deficient 
UV-irradiated virus, intact RV1B increased the mRNA expression of IFN-β , IFN-λ1 and 
IFN-λ2/3, as well as the expression of several interferon-stimulated genes (ISGs) 
including IRF7, RIG-I, MDA5 and TLR3 (Figure 2-1). The peak level of mRNA 
expression was 24 h post-infection, except in the case of IFN-β, which was 48 h post-
infection. The fold-induction varied widely, from 4-fold (TLR3) to approximately 
27,000-fold (IFN-λ2/3). Fold-increases in IFN and ISG mRNA expression tended to be 
higher for genes expressed at lower levels as baseline, as measured by cycle number 
(Table 2-1).  RV1B infection also increased the protein expression of IFN-λ1, IP-
10/CXCL-10 and IL-8/CXCL-8 (Figure 2-2 A-C). However, there was no induction of 
IRF7 protein expression (Figure 2-2D). Nevertheless, these data, combined with 
increases in RIG-I and MDA5 protein abundance (see below), demonstrate that RV 
induces a robust, replication-dependent innate immune response at both the mRNA and 
protein levels. RV1B infection also increased IFN and ISG mRNA expression in primary 
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Figure 2-1. Fold increase of RV1B-induced IFN and ISG responses in cultured airway 
epithelial cells.  BEAS-2B cells were infected with RV1B or sham (1 h at 33ºC).  Total 
RNA was extracted at 1, 8, 16, 24, 48 and 72 hours after infection. A-G. The expression 
of IFN-β, IFN-λ1, IFN-λ2/3, IRF7, RIG-I, MDA5 and TLR3 at each time point was 
determined by qPCR. The expression of each target gene was normalized to GAPDH.  
Expression levels are represented as the ratio of the response to intact RV vs. the 
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Figure 2-2.  RV1B-induced protein expression of IFNs and ISGs. BEAS-2B cells were 
grown to near confluence and infected with RV1B, UV-irradiated RV1B or sham. A-C.  
Medium supernatants were extracted twenty-four hours after infection for ELISA to 
determine the expression of IFN-λ1, IP-10 and IL-8.  D.  Protein lysates were used to 
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Figure 2-3. RV1B-induced expression of IFNs, ISGs and chemokines in primary 
tracheobronchial epithelial cells.  Primary tracheobronchial epithelial cells were grown 
to near confluence and infected with RV1B or sham. A. Total RNA was extracted 
twenty-four hour after infection, and the expression of IFN-β, IFN-λ1, IFN-λ2/3, IRF7, 
IP-10, IL-8 and GM-CSF determined by qPCR.  Expression levels are represented as the 
ratio of the response to intact RV vs. the response to sham.  The y-axis is in log scale.  B-




Table 2-1.  The effect of RV1B infection on mean cycle threshold (Ct) values of IFN and 










 sham RV1B 
 Ct average SE Ct average SE 
IFN-β 39.47 0.53 30.91 0.30 
IFN-λ1 34.80 0.16 24.23 0.20 
IFN-λ2/3 39.67 0.33 25.30 0.21 
IRF7 24.54 0.20 21.38 0.15 
RIG-I 26.97 0.29 21.19 0.19 
MDA5 26.50 0.20 21.64 0.11 




Table 2-2.  The effect of RV1B infection on mean Ct values of IFN and ISG mRNA 
expression in primary cells. 
 
 sham RV1B 
 Ct average SE Ct average SE 
IFN-β 35.97 2.14 32.75 2.72 
IFN-λ1 33.68 1.69 29.06 2.02 
IFN-λ2/3 35.51 1.64 28.47 2.18 
IRF7 29.94 1.26 29.87 0.16 
RIG-I 28.43 0.31 28.22 0.59 





MDA5 and TLR3, but not RIG-I, are required for RV-induced innate immune responses 
 Viral dsRNA generated during replication may be detected by the PRRs, RIG-I, 
MDA5 and/or TLR3. To determine which PRR is responsible for sensing RV dsRNA and 
inducing the innate immune response, we employed siRNA against RIG-I, MDA5 and 
the TLR3 adaptor protein TRIF/TICAM. Forty-eight h later, cells were infected with 
RV1B, UV-irradiated RV-1B or sham HeLa cell lysate, and the expression of IFNs and 
ISGs was measured by qPCR 24 h after infection. RIG-I expression was knocked down 
by 80-90% following treatment with RIG-I siRNA (Figure 2-4A). Immunoblots also 
showed a significant increase in RIG-I protein expression with RV1B treatment, 
suggesting that expression of RIG-I is inducible. RIG-I siRNA had a slight inhibitory 
effect on the expression of its homologue protein, MDA5 (Figure 2-4B). However, RIG-I 
siRNA failed to decrease RV-induced expression of IFNs or ISGs compared to non-
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Figure 2-4. RIG-I and MDA-5 siRNA knockdown efficiencies. A, B. RIG-I or non-
targeting siRNA was transfected into BEAS-2B cells. After transfection, cells were 
infected with RV1B, UV-irradiated RV1B (UV-RV1B) or sham. After infection, cell 
lysates were probed with antibodies against RIG-I (A) or MDA-5 (B).  Note the 
inductions in RIG-I and MDA5 expression with intact RV, as well as the apparent 
degradation of MDA-5 following viral infection. C, D.  MDA5 or non-targeting siRNA 
was transfected into BEAS-2B cells.  After transfection, cells were infected with RV1B, 
UV-irradiated RV1B (UV-RV1B) or sham. After infection, cell lysates were probed with 
antibodies against either MDA5 (C) or RIG-I (D).  (The blots shown are a representative 
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Figure 2-5. siRNA against RIG-I does not block RV1B-induced IFN and ISG 
expression. RIG-I-specific or non-targeting siRNA was transfected into BEAS-2B cells. 
After transfection, cells were infected with RV1B, UV-irradiated RV1B (UV-RV1B) or 
sham. A-G. Total RNA was extracted and the expression of IFN-β, IFN-λ1, IFN-λ2/3, 
IRF7, IP-10, IL-8 and GM-CSF was determined by qPCR. The expression of each target 
gene was normalized to GAPDH. Expression levels are represented as the fold increase 
vs. sham-infected, non-targeting siRNA-transfected cells.  The y-axis has been broken in 
order to show the effects of siRNA on both basal and maximal gene expression.  Bars 
represent mean ± SEM for four experiments; numbers on top of bars indicate the fold 
increase compared to sham-infected sample within its own siRNA group. These notions 
will apply to similar data in the whole chapter. (*p<0.05 vs. RIG-I siRNA-transfected 
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Figure 2-6. siRNA against MDA5 blocks RV1B-induced IFN and ISG expression.  
MDA5-specific or non-targeting siRNA was transfected into BEAS-2B cells. After 
transfection, cells were infected with RV1B, UV-irradiated RV1B (UV-RV1B) or sham. 
A-G. Total RNA was extracted and the expression of IFN-β, IFN-λ1, IFN-λ2/3, IRF7, 
IP-10, IL-8 and GM-CSF was determined by qPCR. The expression of each target gene 
was normalized to GAPDH. H. To determine the protein expression of IFN-λ1, cell 
supernatants were collected twenty-four hours after infection for ELISA.  Bars represent 
mean ± SEM for 3-5 experiments. (*p<0.05 vs. MDA5 siRNA-transfected RV-infected 





 To examine whether MDA-5 is also required for major group RV-induced IFN 
responses, we repeated our experiment using RV39. BEAS-2B cells were transfected 
with either MDA5 or non-targeting siRNA and then infected with RV39, UV-irradiated 
RV39 or sham HeLa cell lysate. Twenty-four h after infection, cellular RNA was 
extracted to measure the expression of IFNs and ISGs by quantitative PCR (Figure 2-7). 
There was a significant decrease in mRNA expression of IFN-β , -λ1 and -λ2/3 in cells 
transfected with MDA5 siRNA compared to cells transfected with non-targeting siRNA. 
MDA5 siRNA also decreased RV39-induced mRNA expression of the ISGs, IRF7 and 
IP-10/CXCL10. 
 We then sought to determine whether MDA-5 is required for the recognition of 
viral dsRNA in primary tracheal epithelial cells as in BEAS-2B cells.  Primary cells were 
cultured until 70% confluent and then transfected with siRNA against MDA5 or non-
targeting siRNA.  Forty-eight h later, cells were infected with RV1B or UV-irradiated 
RV1B. Cellular mRNA was extracted 24 h after infection to determine mRNA expression 
by qPCR.  Compared to non-targeting siRNA, MDA5 siRNA decreased RV1B-induced 
expression of IFN-β, IFN-λ1, IFN-λ2/3, IRF7 and IP-10/CXCL10 (Figure 2-8). These 
data confirm that MDA5 is required for sensing RV dsRNA and induction of the 
subsequent IFN response in primary cells. 
 Next, we blocked TLR3 signaling using siRNA against TRIF/TICAM, the TLR3 
adaptor molecule.  Again, a high knockdown efficiency was verified by immunoblotting 
(Figure 2-9). Like MDA5 siRNA, TRIF siRNA abolished RV-1B induced expression of 
IFN-β, IFN-λ1, IFN-λ2/3, IRF7 and IP-10/CXCL10, suggesting TLR3 signaling is also 
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Figure 2-7. siRNA against MDA5 blocks RV39-induced IFN and ISG expression.  A-G. 
Total RNA was extracted and the expression of IFN-β, IFN-λ1, IFN-λ2/3, IRF7, IP-10, 
IL-8 and GM-CSF was determined by qPCR. The expression of each target gene was 
normalized to GAPDH. Bars represent mean ± SEM for three experiments. (*p<0.05 vs. 
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Figure 2-8. siRNA against MDA5 blocks RV1B-induced IFN responses in primary 
tracheal epithelial cells. A. MDA5 siRNA or non-targeting siRNA was transfected into 
primary tracheobronchial epithelial cells. After transfection, cells were infected with 
RV1B or UV-irradiated RV1B. After infection, cell lysates were probed with anti-MDA5 
antibody. The blot shown is typical for three experiments.  B-H. Total RNA was 
extracted and the expression of IFN-β, IFN-λ1, IFN-λ2/3, IRF7, IP-10, IL-8 and GM-
CSF was determined by qPCR. The expression of each target gene was normalized to 
GAPDH. Bars represent mean ± SEM for three experiments.  (*p<0.05 vs. MDA5 
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Figure 2-9. siRNA against TRIF blocks RV-induced IFN and ISG expression. A. TRIF 
siRNA or non-targeting siRNA was transfected into BEAS-2B cells. After transfection, 
cells were infected with RV1B, UV irradiated-RV1B or sham. After infection, cell 
lysates were probed with anti-TRIF antibody. B-H. Total RNA was extracted and the 
expression of IFN-β, IFN-λ1, IFN-λ2/3, IRF7, IP-10, IL-8 and GM-CSF was determined 
by qPCR. The expression of each target gene was normalized to GAPDH. Expression 
levels are represented as the fold increase vs. sham-infected, non-targeting siRNA-
transfected cells.   Bars represent mean ± SEM for 4 experiments. (*p<0.05 vs. TRIF 




IRF3 is required for RV1B-induced IFN responses 
 IRF3 is a ubiquitously-expressed transcription factor which regulates type I IFN 
production. To test whether RV1B induces IRF3 activation, BEAS-2B cells were infected 
with RV1B or UV-irradiated RV-1B. Cell protein lysates were collected 12 h after 
infection. IRF3 phosphorylation shift was determined by SDS-PAGE followed by 
immunoblotting using anti-IRF3 antibody (Figures 2-10A, B), and IRF3 dimerization 
determined by native PAGE (Figure 2-10C). PolyI:C, a synthetic dsRNA which induced 
both IRF3 phosphorylation and dimerization, served as a positive control.  We found that 
RV1B, but not UV-irradiated RV-1B, induced IRF3 phosphorylation and dimerization. 
Similar results were observed in primary tracheal epithelial cells (Figure 2-10D). 
 We then examined the requirement of IRF3 in RV-induced IFN responses using 
siRNA against IRF3. IRF3 protein abundance was substantially knocked down by IRF3 
siRNA (Figure 2-11). IRF3 siRNA nearly abolished RV-1B-induced expression of 
ΙFNs β, λ1 and λ2/3, IRF7 and IP-10/CXCL10. However, there was no effect on IL-8 or 
GM-CSF expression. Taken together, these data suggests that IRF3 is activated by RV1B, 
and that IRF3 is required for RV-induced IFN responses, as well as the expression of 
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Figure 2-10. RV-induced IRF3 activation in cultured BEAS-2B and primary airway 
epithelial cells.  A. BEAS-2B cells were infected with RV1B or UV-irradiated RV1B (1 
h at 33ºC) at MOI=10.  Cell lysates were collected and probed with anti-IRF3 antibody. 
Poly I:C served as a positive control.  IRF3 protein is visualized as two bands, an upper 
phosphorylated form and a lower unphosphorylated form. B. Densitometry of IRF3 
phosphorylation is provided. Bars represent mean ± SEM for 3 experiments. C. Cellular 
proteins were also subjected to native-PAGE to resolve the dimerization of IRF3. Poly 
I:C served as a positive control. IRF protein is visualized as two bands, an upper dimer 
and a lower monomer. (The blot shown is a representative of five individual experiments.)  
D. Primary tracheobronchial epithelial cells were infected with RV1B or UV-irradiated 
RV1B. Upper panel: cell lysates were collected twelve h after infection and probed with 
anti-IRF3 antibody. Poly I:C served as a positive control. Lower panel: cellular proteins 
were subjected to native-PAGE to resolve the dimerization of IRF3. Poly I:C served as a 
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Figure 2-11. siRNA against IRF3 blocks RV-induced IFN and ISG expression. A. 
IRF3 siRNA or non-targeting siRNA was transfected into BEAS-2B while seeding. After 
transfection, cells were infected with RV1B, UV-irradiated RV1B (UV-RV1B) or sham. 
A. Cell lysates were probed with anti-IRF3 antibody. (The blot shown is representative of 
3 separate experiments.) B-H. Total RNA was extracted and the expression of IFN-β, 
IFN-λ1, IFN-λ2/3, IRF7, IP-10, IL-8 and GM-CSF was determined by qPCR. The 
expression of each target gene was normalized to GAPDH.  Bars represent mean ± SEM 





IRF3 functions downstream of MDA5 signaling 
 RIG-I/MDA5 and TLR3 signaling pathways converge on a common TRAF3 
(TNF receptor associated factor 3) adapter complex, which then activates two IRF3 
kinases, TBK1 and IKK-ε (7). To examine whether IRF3 functions downstream of 
MDA5 in airway epithelial cells, BEAS-2B cells were transfected with either MDA5 
siRNA or non-targeting siRNA, and then infected with RV-1B, UV-irradiated RV-1B or 
sham HeLa cell lysate. IRF3 dimerization was resolved by native PAGE (Figure 2-12). 
We found that MDA5 and TRIF siRNA each caused a partial reduction in RV-induced 
IRF3 dimerization compared to non-targeting siRNA-transfected cells, confirming in 
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Figure 2-12.  siRNA against TRIF, MDA5, but not RIG-I, reduced RV1B-induced 
IRF3 dimerization. A. RIG-I, MDA5, TRIF siRNA or non-targeting siRNA was 
transfected into BEAS-2B. After transfection, cells were infected with RV1B, UV-
irradiated RV1B or sham. After infection, cell lysates were probed with anti-IRF3 
antibody. Poly I:C served as a positive control. B. IRF3 dimer to monomer ratio was 





Host pathogen recognition, as reflected by the induction of type I interferons is 
mediated by activation of pattern recognition receptors. The membrane dsRNA receptor, 
TLR3, and the recently-identified cytoplasmic dsRNA receptors, RIG-I and MDA5, are 
responsible for sensing viral dsRNA (24). Although all three receptors can recognize 
viral dsRNA, the engagement of receptor and viral dsRNA seem to be cell type and virus-
specific.  RIG-I-deficient mice fail to produce type I IFNs in response to the negative-
sense single-stranded RNA (ssRNA) viruses Newcastle disease virus, Sendai virus, 
vesicular stomatitis virus and influenza virus, and to the positive-sense ssRNA Japanese 
encephalitis virus, whereas MDA5-deficient mice fail to detect EMCV, a positive-sense 
ssRNA picornavirus (9). Whereas MDA5 is essential for induction of type I IFNs after 
infection with EMCV in fibroblasts and conventional dendritic cells, plasmacytoid DC 
use the TLR system for viral detection (9). While these results are compelling, it seems 
premature to conclude that all picornaviruses are sensed by MDA5 in all cell types, 
because only cardioviruses have been studied.  
 In this manuscript, we found that infection of BEAS-2B and primary tracheal 
epithelial cells with RV induced substantial increases in IFN and ISG mRNA expression. 
In limited studies, we also found similar changes in gene expression following infection 
with major and minor group virus. Due to the low level of baseline IFN expression, the 
fold-increases in IFN expression were quite high, perhaps artificially so. However, 
increases in IFN-λ1, IP-10/CXCL-10, RIG-I and MDA-5 were verified by ELISA and 
immunoblotting, implying that RV significantly increases IFN responses in airway 




RIG-I, are required for maximal sensing of RV dsRNA in human airway epithelial cells.  
Transfection of both a human bronchial epithelial cell line (BEAS-2B cells) and primary 
tracheobronchial epithelial cells with siRNA against MDA5, but not non-targeting siRNA, 
significantly inhibited RV1B-induced expression of a type I IFN, IFN-β, as well as a 
number of ISGs. Knockdown of MDA5 also attenuated expression of the type III IFNs 
IFN-λ1 and -λ2/3, which functionally resemble type I IFNs (17) and are also induced by 
RV infection (18). These data are in agreement with previous data suggesting MDA5 is 
required for sensing picornavirus dsRNA (9). On the other hand, our data contrast with 
previous data from A549 alveolar type II epithelial cells showing that RIG-I and TLR3, 
but not MDA5, are required for sensing human RSV, a paramyxovirus (8). Thus, in the 
airway epithelium, recognition of viral dsRNA is indeed virus type-specific.   
 We also examined the contribution of IRF3 to RV-induced responses in airway 
epithelial cells. IRF3 siRNA nearly abolished IFN and ISG expression. MDA5 and TRIF 
knockdown also decreased IRF3 dimerization. These data are consistent with the idea 
that TLR3 and MDA5 regulate IFN expression via a common downstream intermediate, 
IRF3.  
 In contrast to siRNA against MDA5, siRNA against RIG-I had no effect on RV-
induced IRF3 dimerization or IFN expression. The divergent roles of RIG-I and MDA5 
in the context of RV infection suggest that the two homologous helicases function 
distinctly from each other. Further, though RIG-I expression was induced after RV 
infection, RIG-I apparently cannot compensate for reduced expression and/or function of 




 Using siRNA against MDA5 and IRF3, we found that MDA5/IRF3 signaling is 
required for RV-induced IFN, but not IL-8 expression. Indeed, expression of IL-8 and 
GM-CSF were often paradoxically increased. Previous studies have shown that RV-
induced IL-8 expression is strictly regulated by the transcription factor NF-κB (14, 19). 
The initial phase of IL-8 expression is also replication-independent (14, 20-22). 
Inhibition of dsRNA sensing would therefore not be expected to reduce IL-8 expression. 
Further, the upregulation of pro-inflammatory cytokine expression following MDA5 and 
IRF3 knockdown may represent a compensatory mechanism by which the airway 
epithelial cells increase immune surveillance when the IFN response is suppressed.   
 We previously showed that TLR3 was partially required for RV39-induced IL-8 
expression in 16HBE14o- cells (12). In the present study, we could not verify TLR3 
knockdown by immunoblotting or flow cytometry in BEAS-2B cells (not shown), leading 
us to employ siRNA against TRIF. In contrast to MDA-5 knockdown, inhibition of TLR3 
signaling using TRIF siRNA inhibited both IFN and IL-8 expression. Based on our 
previous result, the complete effect of TRIF siRNA on IFN signaling was unexpected.  It 
is conceivable that TRIF is coupled to other, as yet unknown pattern recognition 
receptors, and that the reduction in IFN expression induced by TRIF knockdown is not 
solely due to TLR3-linked signaling. In any event, the differential effects of MDA-5 and 
TRIF siRNA on IL-8 expression suggest that, although NF-κB and IRF3 are both 
components of the same transcriptional enhanceosome in the regulation of IFNs, ISGs 
and inflammatory cytokine IL-8 (23, 24), their requirement for gene expression may vary 
for different target genes, perhaps depending on the organization of IFN-stimulated and 




 It has recently been reported that picornaviruses may develop strategies to escape 
host immune surveillance. Hepatitis A virus has been shown to suppress RIG-I-mediated 
signaling in fetal rhesus monkey kidney (FRhK-4) cells (25). Poliovirus infection induces 
cleavage of MDA5 in HeLa cells (26). In A549 human alveolar type II alveolar epithelial 
cells, RV14 infection fails to induce high levels of IFN, apparently by interfering with 
IRF3 dimerization (27). In this study, RV1B induced robust IRF3 dimerization and IFN 
responses in both BEAS-2B and primary bronchial epithelial cells. Also, while we did 
indeed observe apparent degradation of MDA5 following viral infection (Figure 5), the 
total protein abundance of MDA5 was still substantially increased 24 h after RV 
inoculation. Taken together, these data suggest an intact host innate immune defense 
against RV1B dsRNA.  
We confined most of our studies of RV-induced IFN responses to the minor group 
serotype RV1B. However, IFN expression by RV39, a major group virus, was also 
blocked by MDA-5 but not RIG-I siRNA. This was not unexpected, as RV1B and RV16, 
another major group serotype, have been shown to induce nearly identical patterns of 
gene expression in primary cultured airway epithelial cells (28). We have found that 
infection with RV1B and RV39 induce similar levels of Akt phosphorylation and IL-8 
expression in cultured 16HBE14o- human bronchial epithelial cells, and that inhibition of 
PI 3-kinase blocks both RV1B- and RV39-induced IL-8 expression induced by either 
virus (29). Thus, there are ample data suggesting that major and minor subgroup RV 





In conclusion, we have shown for the first time that MDA5, TLR3 and IRF3 are 
each required for maximal RV-induced IFN responses. Viral infections, most commonly 
caused by RV, are the most frequent cause of asthma exacerbations, and account for a 
substantial percentage of chronic obstructive pulmonary disease exacerbations (1).  
Bronchial epithelial cells isolated from patients with asthma have been demonstrated to 
have an incomplete innate immune response to rhinovirus infection, with deficient type I 
IFN-β and type III IFN-λ production (18, 30). Further understanding of the biochemical 
signaling pathways regulating RV-induced IFN expression may therefore provide insight 
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MDA5 and TLR3 signaling initiate pro-inflammatory signaling pathways leading to 
rhinovirus-induced airways inflammation and hyperresponsiveness 
 
Summary 
Rhinovirus (RV) is the most frequent cause of asthma exacerbations. We 
previously demonstrated in cultured human bronchial epithelial cells that TRIF, the 
adaptor protein for TLR3, and MDA5 are each required for maximal RV1B-induced IFN 
responses. However, in vivo, the overall airway response to viral infection likely 
represents a coordinated response integrating both antiviral and pro-inflammatory 
pathways. Therefore, we examined the airway responses of TLR3- and MDA5-deficient 
mice to infection with RV1B, a minor group virus which replicates in mouse lungs. TLR3 
null mice showed essentially normal IFN responses and unchanged viral titer. MDA5 
mice showed a delayed type I IFN and attenuated type III IFN response to RV1B 
infection, leading to a transient defect in viral clearance. Further, RV-infected TLR3- and 
MDA5-deficient mice showed reduced lung inflammatory responses and reduced airways 
cholinergic responsiveness. Finally, RV-infected MDA5 null mice with allergic airways 
disease showed lower viral titers despite deficient IFN responses, as well as decreased 
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airway inflammatory and contractile responses. Together, these results suggest that, in the 
context of RV infection, TLR3 and MDA5 individually initiate pro-inflammatory 
signaling pathways leading to airways inflammation and cholinergic hyper-
responsiveness, implying that TLR3 and MDA5 signaling might be maladaptive 
following RV infection.   
 
Introduction 
Rhinovirus (RV) is the most frequent cause of acute respiratory tract infection in 
humans. RV infection is typically responsible for upper respiratory symptoms including 
rhinorrhea, sore throat, nasal congestion, sneezing, cough, and headache. More 
importantly, RV has emerged as the most frequent pathogen associated with 
exacerbations of asthma (1, 2).   
RV is a positive sense single-stranded RNA (ssRNA) virus from the 
Picornaviridae family. After endocytosis, RV RNA is inserted into the cytosol, where 
viral replication occurs. During replication, a double-stranded RNA (dsRNA) 
intermediate is formed, the main form of viral genome inside the cell. The mechanisms 
by which RV causes asthma exacerbations are not fully established, but current evidence 
indicates that the immune response is critical in this process. The first line of defense 
against RV infection is the innate immune system. Innate pathogen sensors detect viral 
products and respond by initiating a signaling cascade that leads to a rapid antiviral 
response involving secretion of IFNs and inflammatory cytokines. RV induces the 
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expression of both type I (e.g., IFN-α, IFN-β) and type III IFNs (in mice, IFN-λ2/IL-28A, IFN-
λ3/IL-28B). Though they signal through the engagement of different receptor complexes, the 
intracellular signaling program activated by type I and type III IFNs is very similar, as evidenced 
by the cellular gene expression profiles induced after stimulation with IFN-λ versus IFN-α (3). 
However, whereas IFN-α receptor complex is expressed ubiquitously, the IL-28 receptor is only 
expressed in few cell types, notably epithelial cells (4). The preferential expression of IFN-λ 
receptors on epithelial surfaces may allow the host to rapidly eliminate viruses at the major 
portals of entry into the body before infection is established, and without activating other arms of 
the immune system.  
Several pattern recognition receptors have been shown to be responsible for 
binding viral dsRNA and initiating the IFN response. RIG-I and MDA5 are homologous 
proteins located within the cytoplasm, whereas TLR3 is located mainly on the endosomal 
membrane and plasma membrane. RIG-I has been shown to preferentially recognize 5’ 
phosphorylated short ssRNA, whereas MDA5 recognizes long dsRNAs (3-6). Thus, RIG-
I has been shown to detect negative-strand viruses such as influenza, paramyxovirus and 
RSV (7), as well as some positive-strand Flaviviruses. In comparison, MDA5 has been 
shown to selectively detect positive-strand viruses including picornaviruses (EMCV, 
Mengo virus and Theiler’s virus). Previously, we demonstrated in cultured human 
bronchial epithelial cells that MDA5 and TIR-domain-containing adapter inducing 
interferon-β (TRIF), the adaptor protein for TLR3, are each required for maximal RV1B-
induced IFN responses (8).  Knockdown of RIG-I had no effect on IFN responses. TRIF, 
but not MDA5, was required for maximal pro-inflammatory cytokine expression (8). 
TLR3 is partially required for HRV39-induced IL-8 expression in 16HBE14o- human 
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bronchial epithelial cells (9), as well as HRV1A-induced MUC5AC expression in NCI-
H292 mucoepidermoid carcinoma cells (10).  
However, in vitro studies may not truly represent the complicated situation in 
vivo, where multiple cell types are involved.  Further, the overall airway response to viral 
infection likely represents a coordinated response integrating both antiviral and pro-
inflammatory pathways. For example, it has been proposed that asthmatics are 
susceptible to RV infection due to deficient IFN production. RV-infected airway 
epithelial cells from asthmatic subjects show impaired production of IFN-β  and -λ (11, 
12) and asthmatics experimentally infected with RV16 showed a reduced IFN-γ/IL-5 
mRNA ratio in their sputum (13). According to the theory, reduced IFN responses, in 
turn, lead to increased viral-mediated inflammation. However, it is also conceivable that 
reduced RV-induced IFN responses are coupled with attenuated airways inflammation 
and hyperresponsiveness. For example, pneumovirus-infected IFNαβ receptor null mice 
show fewer BAL leukocytes and prolonged survival despite increased virus titers (14).  
To address these questions, we examined the airway responses of TLR3- and MDA5-




Materials and methods 
Animals 
B6;129S1-Tlr3tm1Flv/J (TLR3 -/-) and B6;129SF2/J control mice were purchased 
from Jackson Laboratories (Bar Harbor, MA). MDA5-/- mice were bred on a >99.5% 
C57BL/6 background, as described (16). Control C57BL/6J mice were also purchased 
from Jackson Laboratories. Six-to-eight week old female mice were used in this study. 
All mice were housed in a specific pathogen-free area within the animal care facility at 
the University of Michigan. The protocol was approved by the Institutional Animal Care 
and Use Committee.  
Generation of RV and titer determination. 
RV1B (ATCC, Manassas, VA) was concentrated, purified and titered as described 
previously (17, 18). Viral titer was determined by plaque assay (19). To produce 
replication-deficient virus, RV1B was UV-irradiated using a CL-1000 crosslinker (UVP, 
Upland, CA).  
RV exposure and ovalbumin (OVA) sensitization/challenge.   
Mice were inoculated intranasally with 45 μl of 1x108 TCID50/ml RV1B, UV-
irradiated RV or an equal volume sham HeLa cell lysate (15).  For OVA sensitization, 
mice were injected intraperitoneally on days 1 and 7 with 0.2 ml PBS or a solution of 
alum and 100 μg endotoxin-free OVA (Sigma-Aldrich, St. Louis, MO).  Next, mice were 
challenged intranasally with 50 μl of PBS or 100 μg OVA on days 14, 15 and 16.  





To quantify inflammatory cells, lung digests were obtained by mincing the tissue, 
proteolysis in collagenase type IV (Gibco Invitrogen, Carlsbad, CA) and straining 
through a 70 μm nylon mesh (BD Falcon, San Jose, CA), as described (20). The resulting 
pellet was treated with red blood cell lysis buffer (BD Pharmingen, San Diego, CA) and 
leukocytes were enriched by spinning the cells through 40% Percoll (Sigma-Aldrich).  
The total cell count was determined on a hemocytometer. Cytospins were performed 
from lung digested leukocytes and were then stained by Diff-Quick method (Dade 
Behring, Newark, DE). Differential counts were determined by counting 200 cells per 
slide.  
Measurement of airways responsiveness. 
Mice were anesthetized with sodium pentobarbital (50 mg/kg mouse, 
intraperitoneal injection) and a tracheostomy performed. Mechanical ventilation was 
performed and total respiratory system measured using a Buxco FinePointe operating 
system (Wilmington, NC). Airway responsiveness was assessed by measuring changes in 
resistance in response to increasing doses of nebulized methacholine, as described (15). 
Histology. 
Lungs were fixed in 10% formalin at an inflation pressure of 30 cmH2O overnight, 
transferred to 70% ethanol and paraffin embedded. Five μ sections were stained with 




 Total lung RNA was extracted using the RNeasy kit (Qiagen, Alameda, CA) and 
then transcibed to first-strand cDNA using Taqman reverse transcription reagents 
(Applied Biosystems Life Technologies, Carlsbad, CA). First-strand cDNA was then 
used to quantify the expression of IFN-α, IFN-β, IFN-λ2, IFN-λ3, IFN response factor 
(IRF)-7, CXCL10/IP-10, IFN-γ, CXCL1/KC, CXCL2/MIP-2, CCL2/MCP-1, and 
CCL11/eotaxin-1 by quantitative two-step real time PCR using specific Syber green 
primers. All primers were designed and purchased from IDT (Coralville, IA). The signal 
was normalized to GAPDH and expressed as fold-increase over sham.  
Cytokine production 
Lungs were homogenized in 1 ml PBS with protease inhibitor cocktail, spun for 
15 minutes at 1500 g, and the supernatant assayed for CXCL1, CXCL2 and IFN-β by 
ELISA (R&D Systems, Minneapolis, MN; PBL InterferonSource, Piscataway, NJ).  
Presence of viral RNA 
RNA was extracted from lungs of mice using Trizol reagent (Sigma-Aldrich, St. 
Louis, MO) and analyzed for the presence of viral RNA by reverse transcriptase-PCR. 
uantitative one-step real time PCR for positive-strand viral RNA was conducted using 
RV-specific primers and probes (forward primer: 5'-GTG AAG AGC CSC RTG TGC T-
3'; reverse primer: 5'-GCT SCA GGG TTA AGG TTA GCC-3’; probe: 5'-FAM-TGA 
GTC CTC CGG CCC CTG AAT G-TAMRA-3’ (12). Copy numbers of positive strand 
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viral RNA were normalized to 18S RNA, which was similarly amplified using gene-
specific primers and probes. 
Data analysis 
SigmaStat computing software (SPSS, Chicago, IL) was used for data analysis. 
Data are represented as mean±SEM. Statistical significance was assessed by one- or two-
way analysis of variance (ANOVA). Differences identified by ANOVA were pinpointed 




TLR3 deficiency does not alter RV1B-induced type I IFN responses. 
Our previous studies in cultured airway epithelial cells demonstrated that TRIF, 
the adaptor protein for TLR3, is required for maximal RV-induced IFN expression. 
However, while the airway epithelium is a major target of RV infection, other cell types 
such as monocytes and macrophages may also be infected (21). To determine whether 
TLR3 is required for RV1B-induced airway IFN responses in vivo, we studied TLR3-/- 
mice and their strain- and age-matched controls. Mice were inoculated intranasally with 
sham, replication-deficient UV-irradiated RV1B or intact RV1B. Lungs were harvested at 
4-96 h after infection. Four h after infection, there was no induction of IFN-α gene 
expression in RV1B-infected control mice or TLR3-/- mice (Figure 3-1a). By 24 h, 
compared to sham- or UV-RV1B-infected mice, RV1B-induced IFN-α expression was 
significantly elevated in both control and TLR3-/- mice. There was no difference in IFN-
α expression between strains. IFN-α mRNA expression peaked 24 h post-infection and 
decreased thereafter. The mRNA expression pattern of another type I IFN, IFN-β, was 
similar to that of IFN-α (Figure 3-1b). TLR3-/- mice did not show a lower level of IFN-β 
mRNA expression compared to control mice. Accordingly, there was no difference in 
lung IFN-β protein between RV1B-infected control and TLR3-/- mice (Figure 3-1f).  
Type III IFNs utilize a receptor complex different from that of type I IFNs, but 
both types of IFN induce STAT1, 2 and 3 activation. We therefore measured the 
expression of IFN-λ2 and IFN-λ3 in RV1B-infected wild-type and TLR3 -/- mice 
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(Figures 3-1c, 1d). mRNA levels of both IFN-λ2 and IFN-λ3 were decreased in RV1B-
infected TLR3-/- mice compared to controls, though the change did not achieve statistical 
significance. By 48 h, differences in IFN expression between strains were less apparent.  
The expression of IRF7, an IFN-stimulated gene, was not different between control and 
TLR3-/- mice at any time point (Figure 3-1e).  
TLR3-deficiency does not change viral titer in the lung  
To determine whether TLR3 plays a role in viral clearance, we determined viral 
titer in the whole lung by plaque assay. Control and TLR3-/- mice showed a whole lung 
viral titer of approximately 103 PFU/ml 24 h after infection (Figure 3-2a). Viral copy 
number at various time points was also determined by qPCR (Figure 3-2b). There was no 
difference in viral copy number between the control and TLR3-/- mice. Together, these 
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Figure 3-1. RV1B-induced expression of IFNs and interferon-stimulated genes in 
TLR3-/- mice. TLR3-/- and their control mice were inoculated with sham, UV-irradiated 
RV1B (UV RV1B), or intact RV1B. Lungs were harvested at 4, 24, 48, and 96 h after 
infection. A-E. The expression of IFN-α, IFN-β, IFN-λ2, IFN-λ3, and IRF7 at each time 
point was determined by qPCR. F. IFN-β protein production was measured by ELISA at 
24 h post-infection. The expression of each target gene was normalized to GAPDH.  Data 





















































Figure 3-2. Viral copy number and titer changes in the lungs of control and TLR3-/- 
mice.  TLR3-/- and their control mice were infected with RV1B.  Lungs were harvested 
at 4, 24, 48, and 96 h post infection. A. Total lung titer at 24 h post-infection was 
determined by plaque assay. B. RV1B copy number at each time point was determined by 








TLR3 signaling is required for RV1B-induced inflammatory responses.  
Previously, we showed that TLR3 is required for RV-induced CXCL8/IL-8 
expression in cultured airway epithelial cells (9). We found similar results in vivo using 
TLR3-/- mice: Twenty-four h post-infection, RV1B-infected TLR3-/- mice displayed 
significantly decreased mRNA expression of genes encoding the neutrophil 
chemoattractants CXCL1/KC and CXCL2/MIP-2 (Figures 3-3a, b). Their lung protein 
levels were also significantly decreased compared to control mice (Figures 3-3f, g). 
mRNA expression of three additional pro-inflammatory cytokines, CCL2/MCP-1, 
CXCL10/IP-10, and CCL11/eotaxin-1, were also significantly reduced (Figures 3-3c-e). 
These data suggest that TLR3 is required for RV1B-induced inflammatory responses, in 
particular the expression of neutrophil chemokines. Accordingly, 24 h after infection, 
there were significantly fewer neutrophils in the lungs of RV1B-infected TLR3 -/- mice 
compared controls (Figure 3-3h). These results were reflected in hematoxylin- and eosin-
stained lung sections (Figure 3-4a). Sham-infected control and TLR3-/- mice showed 
uninflamed airways, whereas RV1B-infected control mice displayed increased 
peribronchial inflammation. In contrast, inflammation was significantly alleviated in the 
lungs of RV1B-infected TLR3-/- mice.  
TLR3 is required for RV1B-induced airway hyper-responsiveness. 
We have previously shown that RV1B-induced airways cholinergic hyper-
responsiveness in naïve mice is dependent on CXCR2 and airway neutrophilic 
inflammation (22). Since RV1B-infected TLR3 -/- mice showed significant reductions in 
lung neutrophils, CXCL1 and CXCL2 (each of which are CXCR2 ligands), we 
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hypothesized that RV1B-infected TLR3 null mice would show reduced airway responses 
to methacholine compared to control mice. As noted previously, RV1B-infected control 
mice displayed significantly higher airways responses at 20 and 40 mg/ml methacholine 
compared to sham-infected mice (Figure 3-4b). However, compared to sham-inoculated 
mice, RV1B-induced airway responses were not elevated in TLR3 -/- mice. Together, 
these results demonstrate that TLR3 signaling, while not required for viral clearance, 
initiates a pro-inflammatory signaling pathway leading to airways inflammation and 
hyperresponsiveness. Thus, TLR3-driven innate immune responses to RV are 
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Figure 3-3. RV1B-induced pro-inflammatory cytokine expression in TLR3-/- mice. 
TLR3-/- and their control mice were inoculated with sham, UV-irradiated RV1B (UV 
RV1B), or intact RV1B.  Lungs were harvested 24 h after infection. A-E. The expression 
of CXCL1/KC, CXCL2/MIP-2, CCL2/MCP-1, CXCL10/IP-10 and CCL11/eotaxin-1 
was determined by qPCR. F-G. Protein production of CXCL1/KC and CXCL2/MIP-2 
was measured by ELISA and bioplex assay. The expression of each target gene was 
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Figure 3-4. Airway inflammation and responsiveness in RV1B-infected TLR3-/- and 
control mice. TLR3-/- and their control mice were infected with RV1B. A. Twenty-four 
h after infection, lungs were fixed and stained with hematoxylin and eosin.  B. RV1B-
induced neutrophil infiltration was determined.  Data represent mean±SEM for 3-7 mice 
(*p<0.05, one-way ANOVA).. C. Total respiratory system resistance was determined by 




MDA5 deficiency significantly decreases RV1B-induced IFN responses.  
The recognition of viral dsRNA is pathogen-type specific. We next examined 
whether the role of cytosolic dsRNA receptor in vivo using MDA5-/- mice and age 
matched controls. We infected the mice with sham, UV-irradiated RV1B or RV1B 
intranasally, and harvested the lung at various time points after infection (4-96 h) for total 
RNA and protein extraction. RV1B infection caused a significant induction of the 
expression of type I IFNs, namely IFN-α and IFN-β, in control mice compared to sham 
or UV-RV1B inoculated mice.  However, MDA5-/- mice showed no type I IFN response 
4 and 24 h post-infection (Figures 3-5a, b). The IFN-β protein response 24 h after 
infection was also significantly decreased in MDA5 -/- mice compared to control mice 
(Figure 3-5g). Interestingly, by 48 h post infection, when the type I IFN expression in 
RV1B-infected control mice was essentially over, MDA5 -/- mice showed robust but 
delayed type I IFN response. In contrast, the expression of type III IFNs (IFN-λ2 and 
IFN-λ3) in RV1B-infected MDA5 -/- mice was significantly lower than that of control 
mice throughout the time course studied (Figures 3-5c, d). These data suggest that the 
regulation of type III IFN expression is different from that of type I IFNs.  The 
expression patterns of IRF7 in control and MDA5 -/- mice were similar to that observed 
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Figure 3-5. RV1B-induced expression of IFNs and interferon-stimulated genes in 
MDA5-/- mice. MDA5-/- and their control mice were inoculated with sham, UV-
irradiated RV1B (UV RV1B), or intact RV1B. Lungs were harvested at 4, 24, 48, and 96 
h post infection. A-E. The expression of IFN-α, IFN-β, IFN-λ2, IFN-λ3, and IRF7 at 
each time point was determined by qPCR. F. IFN-β protein production was measured by 
ELISA at 24 h post-infection. The expression of each target gene was normalized to 
GAPDH.  Data represent mean±SEM for 3-7 mice (*p<0.05, one-way ANOVA). 
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MDA5 regulates viral titer change.  
We determined lung viral titer and copy number by plaque assay and qPCR, 
respectively. There was a modest but statistically significant increase in viral titer and 
copy number in MDA5-/- mice compared to that of control mice 24 h post infection 
(Figures 3-6a, b). Viral titer and copy number were indistinguishable between the two 
groups at 48 h. Together, these data suggest that the delayed type I IFN response in 
MDA5 -/- mice is associated with a transient increase in viral titer.  
MDA5 signaling is required for RV1B-induced inflammatory responses. 
To determine whether MDA5 also plays a role in mediating RV1B-induced 
inflammatory responses, we measured the expression of pro-inflammatory cytokines in 
control and MDA5-/- mice. RV1B-infected MDA5-/- mice displayed significantly 
decreased expression of the neutrophil chemo-attractants CXCL1/KC and CXCL2/MIP-2 
at both mRNA and protein levels compared to that of control mice (Figures 3-7a, b and h). 
To varying degrees, CCL2/MCP-1, CXCL10/IP-10, IL-6 and IFN-γ were also decreased 
24 hr post infection (Figure 3-7c-f). There was no induction of CCL11/eotaxin-1 mRNA 
after RV1B infection in control or MDA5-/- mice (Figure 3-7g). These data suggest that 
MDA5 is required for RV1B-induced inflammatory responses in vivo. Accordingly, we 
also found significantly fewer neutrophils in the lungs of RV1B-infected MDA5 -/- mice 
compared to control mice 24 hr after infection (Figure 3-8b). This was reflected in H&E-




MDA5 is required for RV1B-induced airway hyperresponsiveness 
We examined the airway cholinergic responsiveness of RV1B-infected control 
and MDA5 -/- mice 24 h after infection. RV1B-infected MDA5-/- mice displayed 
significantly lower airway responses to methacholine (Figure 3-8c). There was no 
difference in responsiveness between RV1B-infected MDA5-/- mice and sham-infected 





























0 24 48 96
3
4

























Figure 3-6. RV1B titer and copy number in MDA5-/- mice. MDA5-/- and their control 
mice were infected with RV1B. Lungs were harvested at 4, 24, 48, and 96 h after 
infection. A. Lung titer at 24 h post-infection was determined by plaque assay.  B. RV1B 
copy number at each time point was determined by qPCR. RV copy number was 
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Figure 3-7. RV1B-induced pro-inflammatory cytokine expression in MDA5-/- mice. 
MDA5-/- and their control mice were inoculated with sham, UV-irradiated RV1B (UV 
RV1B) or RV1B. Lungs were harvested 24 after infection. A-G. The expression of 
CXCL1/KC, CXCL2/MIP-2, CCL2/MCP-1, CXCL10/ IP-10 and CCL11/eotaxin-1 was 
determined by qPCR. H. Protein production of CXCL1/KC was measured by bioplex 
assay. The expression of each target gene was normalized to GAPDH.  Data represent 






























































Figure 3-8. Airway inflammation and responsiveness in RV1B-infected MDA5-/- and 
control mice. MDA5-/- and their control mice were infected with RV1B. A. Twenty-four 
h after infection, lungs were fixed and stained with hematoxylin and eosin.  B. RV1B-
induced neutrophil infiltration was determined.  Data represent mean±SEM for 3-7 mice, 
*p<0.05, one-way ANOVA). C.  Total respiratory system resistance was determined by 
plethysmography.  Data represent mean±SEM for 3-7 mice (*p<0.05, two-way ANOVA). 
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MDA5 is required for maximal RV1B-induced type I and III IFN responses in mice with 
allergic airways disease. 
Since RV is the most frequent pathogen associated with asthma exacerbations, we 
combined RV infection with a commonly-used model of allergic airways disease, 
ovalbumin-sensitization and challenge. Wild-type and MDA5 -/- mice were injected 
intraperitoneally with PBS or a solution of alum and OVA, and then challenged 
intranasally with PBS or OVA. Mice were infected with RV1B immediately following 
the last OVA or PBS treatment. Lung IFN and inflammatory responses were measured as 
previously described in naïve mice.  
Twenty-four h after infection, RV1B-infected OVA-treated wild-type mice 
displayed significantly increased levels of IFN-β, IFN-λ2 and IFN-λ3 expression 
compared to sham-inoculated OVA-treated mice. IFN responses were severely 
diminished in RV1B-infected OVA-treated MDA5-/- mice (Figures 3-9a-c). To 
determine the effect of reduced IFN expression on RV titer, we measured lung titers.  
Consistent with our previous results (21), after ovalbumin sensitization and challenge, 
both control and MDA5-/- mice showed significantly lower viral titers compared to naïve 
mice, indicating indicating either enhanced viral clearance or perhaps a failure of the virus to 
establish infection (Figure 3-9d). There was no difference observed between OVA-treated 
control or MDA5-/- mice. Thus, in the context of allergic inflammation, MDA5-deficient 
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Figure 3-9. RV1B-induced IFN responses and viral clearance in OVA-treated MDA5-
/- mice. OVA-treated MDA5-/- mice and control mice were infected with sham, or RV1B. 
Total lungs were harvested at 24 post infection. A-C The expression of IFN-β, IFN-λ2, 
IFN-λ3 was determined by qPCR. D. Total lung titer at 24h post infection was 
determined by plaque assay. The expression of each target gene was normalized to 







MDA5 is required for maximal RV1B-induced airways inflammation and hyper-
responsiveness in mice with allergic airways disease.  
We have previously shown that RV1B infection and OVA sensitization and 
challenge have additive effects on lung inflammation in control mice one day after 
infection (21). Thus, as expected, sham-infected OVA treated wild-type mice showed 
more lung inflammation than sham-infected or RV1B-infected naïve wild-type mice. 
Baseline levels of cytokines (IL-6, CCL2/MCP-1, IFN-γ and CCL11/eotaxin-1) were 
increased in the lungs of sham-infected OVA-treated mice. Twenty-four h after RV1B 
infection, CXCL1/KC, CXCL2/MIP-2, IL-6, CCL2/MCP-1, and IFN-γ expression in 
wild-type mice increased 3-5 fold (Figures 3-10a-e). MDA5 deficiency significantly 
reduced the induction of CXCL1/KC, CXCL2/MIP-2, IL-6, CCL2/MCP-1 and IFN-γ. 
The expression of CCL11/eotaxin-1 mRNA was not significantly elevated 24 h after 
infection and was not different between control and MDA5-/- mice (Figure 3-10f). 
Neutrophil infiltration in the MDA5 -/- mice was significantly lower than wild-type mice 
(Figures 3-11a). There was no significant difference observed in the number of 
macrophages, eosinophils or lymphocytes (Figures 3-11b-d). H&E staining showed less 
inflammation around the airways of RV1B-infected OVA-treated MDA5-/- mice 
compared to wild-type mice (Figures 3-12a). Consistent with the greater amount of 
inflammation present in the lung, RV1B-infected, OVA-treated control mice displayed 
the highest airways responsiveness compared to any other treatment. Airways 
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Figure 3-10. RV1B-induced pro-inflammatory cytokine expression in OVA-treated 
MDA5-/- mice. OVA-sensitized and -challenged MDA5-/- and control mice were 
inoculated with sham or RV1B. Lungs were harvested at 24 and 96 h after infection. A-F. 
The expression of CXCL1/KC, CXCL2/MIP-2, IL-6, CCL2/MCP-1, IFN-γ and 
CCL11/eotaxin-1 was determined by qPCR. The expression of each target gene was 
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Figure 3-11. Early lung inflammation in OVA-treated RV1B-infected MDA5-/- mice 
cell counts. MDA5-/- and their control mice were OVA-sensitized and -challenged and 
then infected with RV1B. Twenty-four h after infection, lungs were digested by 
collagenase. A-D. The number of infiltrated neutrophils, macrophages, eosinophils and 
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Figure 3-12. Early lung inflammation in OVA-treated RV1B-infected MDA5-/- mice: 
histology and airways responsiveness. MDA5-/- mice and their control mice were 
sensitized and challenged with OVA and then infected with RV1B. A. Twenty-four h 
after infection, lungs were fixed and stained with hematoxylin and eosin. B. Total 
respiratory system resistance was determined by plethysmography. Data represent 




Ninety-six h after infection, RV1B-induced airways hyperresponsiveness is 
dependent on CCL11/ eotaxin-1-mediated eosinophilic airway inflammation (21). At this 
time point, in contrast to the other cytokines, IFN-γ mRNA expression increased in both 
control and MDA5-/- mice (Figures 3-13a-f). Also, compared to control mice, RV1B-
induced CCL11/eotaxin-1 and IL-6 levels were significantly decreased in MDA5-/- mice. 
No difference in neutrophil infiltration between wild-type and MDA5 null mice was 
observed. However, eosinophil and macrophage infiltration was significantly lower in 
MDA5-/- mice (Figures 3-13a). Finally, the airways responsiveness of RV1B-infected 
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Figure 3-13. Late lung inflammation in OVA-treated RV1B-infected MDA5-/- mice. 
MDA5-/- and their control mice were sensitized and challenged with OVA and then 
infected with RV1B. A. Ninety-six hour after infection, the number of infiltrated 
neutrophils, macrophages, eosinophils, and lymphocytes was counted. Data represent 
mean±SEM for 4-7 mice (*p<0.05, one-way ANOVA).  B. Total respiratory system 
resistance was determined by plethysmography. Data represent mean±SEM for 4-7 mice 




Pattern recognition receptors regulate multiple effector molecules, including type 
I IFNs and other pro-inflammatory cytokines (23-25). The innate immune response to 
viral infection is specific to cell type/organ as well as to invading pathogen (26, 27). The 
ultimate host response is likely to be an integration of both IFN and pro-inflammatory 
responses. Because viral infections, in particular RV, are the most common cause of 
asthma exacerbations, we examined the roles of the pattern recognition receptors TLR3 
and MDA5 in the response to RV infection. We found that both TLR3 and MDA5 were 
required for RV1B-induced maximal inflammatory responses and airways cholinergic 
hyper-responsiveness in vivo. TLR3 null mice showed more-or-less normal IFN 
responses and normal viral titer. MDA5 mice showed a delayed type I IFN and attenuated 
type III IFN response to RV1B infection, leading to a transient defect in viral titer. 
Further, MDA5 null mice with allergic airways disease showed enhanced viral clearance 
despite deficient IFN responses, as well as decreased airway inflammatory and contractile 
responses. Together, these results suggest that TLR3 and MDA5 individually initiate pro-
inflammatory signaling pathways leading to airways inflammation and cholinergic hyper-
responsiveness.  
Previous studies by our group demonstrated that TLR3 is required for RV39-
induced IL-8 expression in cultured airway epithelial cells (9) and that the TLR3 adaptor 
protein TRIF is required for both IFN and cytokine responses (8). In contrast, the present 
study showed that TLR3 was not required for RV1B-induced IFN responses or viral 
clearance in vivo. The differential effects of TLR3 deficiency on chemokine and IFN production 
98 
 
suggest that, in the context of RV infection, TLR3 preferentially activates NF-κB- rather than 
IRF3-dependent gene expression. This discrepancy may also reflect the cell-type specificity 
of pattern recognition receptors (26, 27). Furthermore, TLR3 is only one of three pattern 
recognition receptors capable of signaling in response to viral infection (the others being 
RIG-I and MDA5). Finally, TLR4 signals through TRIF to upregulate IRF3-dependent 
genes and has been implicated in the innate immune response to vesicular stomatitis virus 
(28, 29). These redundant signaling pathways may explain why TLR3 is dispensable for 
IFN production and protection from RV infection.  
Mice lacking TLRs and key molecules of TLR signaling pathways have been 
shown to display diverse viral infectious phenotypes depending on the host gene-
pathogen combination. Studies have shown that TLR3 plays a protective role against 
various viral infections in vivo. Mice lacking TLR3 display reduced IFN-α/β production 
and an increased viral load against mouse cytomegalovirus infection (30). In response to 
coxsackievirus B4 infection, TLR3-/- mice produce less pro-inflammatory mediators and 
are unable to control viral replication at the early stages of infection, resulting in severe 
cardiac damage and reduced survival (31). On the other hand, alternative studies have 
suggested that TLR3 plays a detrimental role upon viral infection. Despite an increased 
viral load, influenza A virus-infected TLR3-/- animals display significantly reduced pro-
inflammatory mediators, suggesting that TLR3 critically contributes to a detrimental host 
inflammatory response (32). In addition, TLR3 signaling has also been reported to have a 
detrimental effect in phlebovirus and vaccinia infections (33, 34). The role of TLR3 in 
West Nile virus infections is controversial. In one study, TLR3-/- mice displayed 
impaired expression of inflammatory cytokines and IFNs and enhanced viral load in the 
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peripheral blood, but reduced viral load and inflammation in the brain (35). In a second 
study, the absence of TLR3 enhanced mortality and increased viral burden in brain 
neurons but had little effect on peripheral IFN expression or viral load (36). Our study 
demonstrated that, as with influenza infection, TLR3-/- mice displayed a decreased 
inflammatory response upon RV1B infection, resulting in a significantly lower airways 
cholinergic responsiveness, suggesting for the first time that TLR3 signaling is 
maladaptive following RV infection. These data agree with a recent report showing that 
TRIF-/- mice challenged with dsRNA display decreased airway responsiveness and 
pulmonary inflammation compared to control mice (37).  
Unlike TLR3-/- mice, our studies showed that MDA5-/- mice displayed a 
reduction in type I IFN expression after RV1B infection, leading to a transient increase in 
viral titer and copy number 24 h after infection. Interestingly, MDA5-/- mice displayed 
increased IFN-α/β expression 48 h after RV1B infection, suggesting a delayed onset of 
IFN signaling. We speculate that this was due to the compensatory activation of another 
host pattern recognition receptor. On the other hand, MDA5 null mice showed a 
persistent defect in the expression of type III IFNs. These data suggest that type III IFN 
responses are a less critical host defense against RV1B infection and are regulated 
independently of type I IFN responses. In support of this concept, IFN-λ is not required 
for immunity to influenza in wild-type mice, though it protects influenza-infected IFN-
α/β knockout mice (38). The IRF7 response seemed to be more closely associated to type 
I IFN rather than type III IFN responses in both TLR3 and MDA5 knockout mice. 
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Together, these data suggest that MDA5 rather than TLR3 is the primary receptor for 
containing RV replication, and that type I IFNs play a core role in this antiviral event.  
In addition to decreased IFN responses, MDA5-/- mice also displayed reduced 
expression of pro-inflammatory cytokines such as CXCL1, CXCL2, CCL2 and IL-6. The 
coupling of IFN and pro-inflammatory responses has also been observed in other studies. 
Bone marrow-derived dendritic cells from MDA5 -/- mice display significantly lower 
expression of IFN-α, CCL2/MCP-1 and IL-6 against murine norovirus infection 
compared those from control mice (16). On the other hand, reduced viral clearance has 
ultimately led to enhanced inflammatory responses in some models. MDA5-/- mice show 
significantly decreased IFN mRNA expression profiles five days after Sendai virus 
infection but compensatory IL-6 mRNA expression, resulting in increased mortality and 
severe histopathological changes in the lower airways (39). Thus, host inflammatory 
responses in the absence of IFN expression are pathogen-specific: When challenged by 
pathogenic lethal viruses such as Sendai virus, the host initiates inflammatory responses 
to defend against viral invasion. However, when confronted with non-pathogenic viruses 
such as RV, it is advantageous for the host to terminate the inflammatory response, in 
order to avoid adverse effects.   
Despite differences in their IFN responses, TLR3 and MDA5 knockout mice 
displayed reduced expression of the neutrophil chemoattractants CXCL1/KC and 
CXCL2/MIP-2 following RV infection, leading to decreased neutrophil infiltration into 
the airways. Decreased neutrophilic airways inflammation was associated with decreased 
airways responsiveness. This is consistent previous studies from our group showing that 
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CXCR2 ligands are required for RV1B-induced airway inflammation and 
hyperresponsiveness (40).  
It has been proposed that asthmatics are susceptible to RV infection due to 
deficient IFN production. RV-infected airway epithelial cells from asthmatic subjects 
show impaired production of IFN-β  and -λ (11, 12) and asthmatics experimentally 
infected with RV16 showed a reduced IFN-γ/IL-5 mRNA ratio in their sputum (13). To 
examine whether an allergic background alters the response of wild-type and MDA5 
knockout mice to viral infection, we combined RV infection with a commonly-used 
model of allergic airways disease, OVA-sensitization and challenge. First, we found that, 
following OVA treatment, both wild-type and MDA5-/- mice demonstrated reduced viral 
titers following infection with RV. This is consistent with our previous data (21), as well 
as data from guinea pigs that were sensitized to OVA and subsequently infected with 
parainfluenza (41). The precise mechanism for increased viral titer in mice with allergic 
airways disease is unclear. Prior to RV infection, these mice showed increased baseline 
levels of neutrophils, macrophages, lymphocytes, eosinophils, IFN-γ, IL-6 and 
CCL11/eotaxin-1, each of which could have contributed to an antiviral response.  
Eosinophils are known to contain a number of granule proteins that can neutralize viruses, 
such as eosinophil cationic protein and eosinophil-derived neurotoxin, each of which 
possess strong ribonuclease activity (42). Eosinophils have been shown to neutralize 
respiratory syncytial virus in a concentration-dependent manner, and this effect could be 
completely reversed by a ribonuclease inhibitor (43, 44). Second, we found that RV1B-
infected OVA-treated MDA5-/- mice showed significantly reduced IFN and cytokine 
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levels compared to wild-type mice. Reduced cytokine expression, in turn, led to 
persistent attenuations in airway inflammation and responsiveness. Thus, pro-
inflammatory and IFN responses were strictly linked: Reduced IFN responses in MDA5 -
/- mice were associated with less robust, not increased, inflammatory responses. These 
data are consistent with our recent findings in airway epithelial cells isolated from 
patients with COPD (45). These cells showed increases in both pro-inflammatory 
cytokines and IFNs.  
Finally, we would like to add a few comments about our mouse model of human 
RV1B infection. We (15) and others (46) have found that a much higher viral titer is 
required to infect mice compared to humans. This is to be expected, as differences in the 
homology of viral receptors and intracellular signaling mechanisms are likely to restrict 
viral infection and replication in mice. This restriction in viral replication could have 
limited the effects of pattern recognition receptor knockout in our model. On the other 
hand, we have clearly shown that human RV1B replicates to some extent in mouse lungs, 
as evidenced by: 1) the presence of negative-strand viral RNA in the lungs of inoculated 
mice; 2) transmissibility of RV infection from the lung homogenates of inoculated mice 
to cultured HeLa cells; 3) the induction of a robust lung interferon response; and 4) a 
modest increase in lung vRNA following infection(15). In addition, we have demonstrated a 
significant reduction in RV1B clearance in mice chronically treated with 
lipopolysaccharide and elastase, a model of chronic obstructive pulmonary disease in 
which IFN and IL-10  responses to RV1B are deficient (47). 
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 In summary, to our knowledge this is the first study to examine the contribution 
of TLR3 and MDA5 to RV responses in vivo. Our results suggest that TLR3 and MDA5 
individually initiate pro-inflammatory signaling pathways leading to airways 
inflammation and cholinergic hyper-responsiveness. Thus, TLR3- and MDA5-driven 
innate immune responses to RV, a relatively non-pathogenic virus, are maladaptive in 
this model. Therefore, antagonists against TLR3 and MDA5 could provide potential 
therapeutic agents in the treatment of virus-induced asthma exacerbations. Future studies 
focusing on the interactions and coordination between the two receptors would be useful 
in understanding the precise mechanism of RV-induced, pattern recognition receptor-
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Summary, Limitations, and Future Directions 
 
Summary 
Most virus-induced asthma exacerbations in children and at least half of those in 
adults are caused by RV (1-2). While RV has traditionally been regarded as an upper 
respiratory pathogen, recent studies have revealed its presence in the lower airways, 
although the extent of replication remains unknown (3-6). Several studies have reported 
that RV infection can induce IFN and ISG expression in cultured airway epithelial cells 
(7-8). The expression of IFNs is an early event and a major component of the host innate 
immune response. However, the mechanism by which RV infection activates the IFN 
expression signaling pathway is not well understood. 
Host PRRs have become a compelling research topic in the field of innate 
immune responses because they play an essential role in the recognition of the specific 
molecular patterns of different viruses (9). This thesis has three objectives: 1. to 
determine which dsRNA PRRs are required to sense RV dsRNA and trigger downstream 
antiviral signaling events in airway epithelium; 2. to determine the contribution of MDA5 
and TLR3 in RV-induced innate immune responses in vivo; 3. to determine the effect of 
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antiviral IFN responses on airways that have a pre-existing allergic inflammation. To 
achieve these objectives, we first used a human airway epithelium cell line to examine 
the changes in the expression of IFNs and pro-inflammatory genes after RV1B infection; 
then, using our established model of RV infection, we examined the IFN responses and 
pro-inflammatory changes observed after RV inoculation in naïve mice; and finally, we 
extended this line of study to a mouse model of allergic airway disease that we developed 
recently in our laboratory. (10) 
dsRNA produced during viral infection represents an important stimulus of the 
host innate immune response. It is recognized and engaged by three PRRs. TLR3, which 
is localized to the endosomal and plasma membranes, senses viral dsRNA released from 
dying cells and signals through its adaptor protein TRIF (11). RIG-I and MDA5, which 
are localized to the cytosol, sense viral dsRNA in the cytoplasm. (12-13) 
Although all three PRRs recognize viral dsRNA, they appear to be specialized in 
their recognition of particular viruses. RIG-I and TLR3 are required for respiratory 
syncytial virus (RSV)-induced expression of IFN-β and IP-10 in airway epithelial cells 
(14). RIG-I-deficient mice fail to produce type I IFNs in response to infection with 
certain negative-sense ssRNA viruses – NDV, SeV, VSV, and influenza virus – and the 
positive-sense ssRNA Japanese encephalitis virus; whereas MDA5-deficient mice fail to 
produce IFNs in response to EMCV infection (9). The engagement of PRRs also appears 
to be cell type-specific. For example, in fibroblasts and cDCs, MDA5 is essential for the 
induction of type I IFNs against EMCV, a member of picornavirus family; whereas pDCs 
use the TLR system for viral detection (9). While these results are compelling, it seems 
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premature to conclude that all picornaviruses are sensed by MDA5 in all cell types, 
because, to date, studies have been limited to only a few members of the picornovirus 
family (15).  
For the first time, we determined that MDA5 and TRIF, but not RIG-I, are 
required for maximal sensing of RV dsRNA in cultured human airway epithelial cells.  
Transfection of a human bronchial epithelial cell line (BEAS-2B cells) with siRNA 
against MDA5 and TRIF, but not RIG-I or non-targeting siRNA, significantly inhibited 
RV1B-induced expression of type I IFNs, and the IFN-stimulated gene IRF7, but not the 
pro-inflammatory genes GM-CSF or IL-8.  Knockdown of MDA5 and TRIF also 
attenuated the expressions of the type III IFNs IFN-λ1 and -λ2/3, which functionally 
resemble type I IFNs and are also induced by RV infection (16-17). Further, we 
confirmed the role of MDA5 in primary tracheobronchial epithelial cells. These data are 
in agreement with previous data suggesting that MDA5 is required to sense picornavirus 
dsRNA. We also examined the contribution of IRF3 to RV-induced responses in airway 
epithelial cells. IRF3 siRNA nearly abolished RV-induced expressions of IFN and ISG.  
MDA5 and TRIF knockdown also decreased IRF3 dimerization. These data are 
consistent with the idea that TLR3 and MDA5 regulate IFN expression via the same 
downstream intermediate, IRF3.   
Next, we examined the airway responses of TLR3- and MDA5-deficient mice to 
infection with RV1B, a minor group virus that replicates in mouse lungs (18). Compared 
to control mice, TLR3-/- mice showed essentially normal IFN responses and normal viral 
clearance. MDA5-/- mice displayed a delayed type I IFN response and an attenuated type 
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III IFN response to RV1B infection, leading to a transient increase in viral titer. Further, 
RV-infected TLR3 and MDA5 null mice both displayed reduced neutrophil infiltration in 
the lungs, reduced expression of pro-inflammatory chemokines (i.e., MCP-1, MIP-2, and 
KC), and reduced cholinergic responsiveness in the airway, suggesting that both TLR3 
and MDA5 are required for RV-induced airway inflammation in vivo.   
Finally, we tested the impact of MDA5 deficiency on RV-infected airways with 
pre-existing allergic inflammation induced by OVA sensitization and challenge. RV-
infected MDA5-/- mice displayed higher inflammatory responses overall as a result of 
OVA treatment, leading to decreased viral titer despite a deficient IFN response. One day 
after RV infection, the airways of MDA5-/- mice exhibited attenuated contractile 
responses and decreased neutrophilic inflammation; 4 days post-infection, there was 
decreased eosinophilic inflammation. Together, these results suggest that, in the context 
of RV infection, TLR3 and MDA5 each initiate pro-inflammatory signaling pathways 
leading to airway inflammation and cholinergic hyper-responsiveness, implying that 
TLR3 and MDA5 signaling might be maladaptive. 
Although some studies indicate that the susceptibility of asthmatics to RV may be 
due to a deficient IFN response in epithelial cells (17, 19), the evidence is controversial 
and has raised heated debate (20). Our study clearly shows that a deficient IFN response 
need not necessarily exacerbate an asthmatic situation; and may indeed be associated 




Limitations and Future Directions 
RV infection 
In these studies, we infected mice with human minor group serotype RV1B. 
Species differences in the major group virus ICAM-1 receptor present a challenge in 
developing an optimal mouse model for major group RV infection. In addition, we have 
been unable to detect sustained expression of negative-strand viral RNA in C57BL/6 or 
BALB/c mice infected with RV1B, a result that would more faithfully reproduce human 
infection. However, we have shown clearly that human RV1B replicates to some extent 
in mouse lungs: our previous studies revealed the presence of negative-strand viral RNA 
in the lungs of inoculated mice; we have also shown that lung homogenates from RV-
infected mice, when overlayed on Hela cell monolayers, produce cytopathic effects on 
cultured HeLa cells; and we have shown that RV inoculation of naïve mice induces a 
strong IFN response that is dependent on double-stranded viral RNA (18). In addition, we 
have demonstrated a significant increase in RV1B copy number in mice chronically 
treated with lipopolysaccharide and elastase, a model of chronic obstructive pulmonary 
disease in which both IFN and IL-10  responses are deficient (21). Nevertheless, in future 
studies, we might make adjustments in our model to enhance viral replication. For 
example, we could attempt to adapt minor group RV to the mouse by repeatedly passing 
the virus through mouse cells, either in vitro or in vivo. Transgenic mice with an 




Limitations of the allergen sensitization and challenge protocol 
 In our studies, we employed OVA, a chicken egg antigen, to generate an allergic 
response in murine lungs. We used aluminum hydroxide as an adjuvant, which helps to 
process and present the antigen. However, OVA is not a physiologic allergen in humans, 
and human allergen sensitization does not require an adjuvant or systemic administration. 
It is conceivable that the increase in viral clearance we observed after allergen 
sensitization and challenge is an artifact of our allergen sensitization and challenge 
protocol. Future studies should therefore consider other, more physiologic allergens, such 
as cockroach frass or dust-mite extract, which combine both an antigen and protease, 
obviating the need for an adjuvant. . 
Integration of immune responses in the whole animal 
Based on our previously presented data, it should be clear that the overall 
response of the airways to viral infection represents the integration of a number of 
overlapping and sometimes conflicting pathways. First, the response includes both 
antiviral pathways, driven by viral dsRNA and pattern recognition receptors, and NF-κB-
mediated pro-inflammatory pathways. NF-κB may be activated by both early events in 
the viral life cycle (i.e., binding and endocytosis) and viral replication (22).    
Second, the response is mediated by a number of different cell types. Until 
recently, the main target of RV infection in the lung was thought to be the airway 
epithelial cell. The epithelial surface is regarded as the first line of host defense. Research 
has shown that there is a prominent early activation of the IFN-signaling protein Stat1 
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when airway epithelial cells are infected with SeV (23). Infected Stat1-/- mice exhibited 
increased viral replication and neutrophilic inflammation in concert with overproduction 
of TNF-α and the neutrophil chemokine CXCL2. After reconstitution with wild-type 
bone marrow, Stat1-/- mice remain susceptible to infection with SeV. This suggests that 
the predominant IFNs originate from lung epithelium instead of hematopoietic cells, 
another potential source of IFN production. We therefore initially examined the pattern 
recognition receptors responsible for RV-induced IFN production in cultured airway 
epithelial cells. However, it has recently become apparent that RV may infect resident or 
infiltrating inflammatory cells. Recent immunohistochemical studies from our laboratory 
have shown that RV can infect lung macrophages in vivo (10). We (10) and others have 
also shown that monocytes and macrophages produce IFNs and other pro-inflammatory 
cytokines, including TNF-α and MCP-1 in vitro (24-25). Therefore, the IFN and 
inflammatory responses we observed in mice likely arise from both lung epithelial and 
immune cells, which may amplify the antiviral responses from epithelium alone.  
Third, there are temporal aspects of the response which may be carried out by 
different cell types, distinct pattern recognition receptors, or even distinct signaling 
pathways within the same cell. Compared to control mice, MDA5-/- mice displayed a 
delayed type I IFN response after RV infection. The precise mechanism of this 
compensatory response is not known. In the absence of MDA5, some other dsRNA PRR, 
such as TLR3, may be activated at a later point to induce type I IFN expression. Little is 
known about the relative contributions of these receptors or their cooperative effects on 
antiviral defense (26-27). One study showed that RIG-I and TLR3 mediate RSV in a 
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temporal manner, with RIG-I mediating an early response and TLR3 mediating a later 
response (28). In contrast, another study suggested opposite roles for TLR3 and RIG-I in 
the inflammatory response to dsRNA in a tumor cell line (29). Given the physiological 
location of these receptors and the insertion location of RV dsRNA, it is conceivable that 
the TLR3 system is activated only after lysis of infected cells, leading to free dsRNA for 
endocytosis. Future studies using double-knockout mice of MDA5 and TLR3 may 
provide valuable information about whether TLR3 is indeed the receptor that is activated 
in a delayed fashion in MDA5-/- mice following RV infection and about the cooperation 
of these receptors in a host defense system against RV infection. It is plausible that the 
double knockout mice will display a persistently decreased, instead of a merely delayed, 
type I IFN response after RV infection.  
Fourth, there may be a spatial aspect of coordination among these receptors, given 
their different cellular locations. As noted above, early responses may require recognition 
of dsRNA in the cytoplasm by MDA-5, whereas later responses may require recognition 
of free dsRNA by plasma membrane/endosomal TLR3.    
On a related note, since these receptors tend to share common downstream 
signaling pathways, the mechanism by which both MDA5 deficiency and TLR3 
deficiency each attenuate RV-induced inflammation is unclear. Unlike RV-induced IFN 
responses, there does not seem to be a redundancy between MDA5 and TLR3 when it 
comes to chemokine responses. The two receptors do not appear to compensate for each 
other in regulating RV-induced inflammatory responses in vivo. The explanation for this 
is unclear, but it is conceivable that different cell types utilize the two different receptors 
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in vivo, and that each cell type is capable of producing a significant inflammatory 
response. It is also possible that the absence of TLR3/MDA5-mediated signaling causes 
dysregulation of normal innate immune system activation.  
Downstream of PRRs are common kinases that are required for the expression of 
IFNs and cytokines in response to viral infection (30-31). The IκB kinases IKK-α and 
IKK-β and the IKK-related kinases TBK-1 and IKK-ε have essential roles in innate 
immunity through signal-induced activation of NF-κB, IRF3, and IRF7. These kinases 
could participate in compensatory responses following knockout of upstream PRRs.  In 
fact, since these kinases are the converging points of upstream receptor signaling, their 
function could substitute for a double or triple knockout of upstream receptors. Over-
expression of IKK-ε results in restoration of defective antiviral IFN signaling against 
hepatitis C virus infection (32). Conversely, it is plausible that the deficiency of these 
kinases may abolish the RV-induced innate immune response more thoroughly than each 
individual receptor. It has been shown that mice lacking IKK-ε produce normal amounts 
of IFN-β, but are hyper-susceptible to influenza virus infection because of a defect in the 
IFN signaling pathway (33). Future studies using IKK-ε knockout mice from the Saltiel 
laboratory at the University of Michigan may provide insight into the role of this kinase 
against RV infection. It is reasonable to speculate that the deficiency of IKK-ε may result 
in a complete shut-down of RV-induced IFN and inflammatory responses. However, 
given that the precise role of non-canonical IKKs is not completely understood, and the 
overlapping, cross-linking nature of the inflammatory pathways (34-35), the effects of 
IKK-ε knockout are difficult to predict.  
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Throughout the studies in this thesis, we have examined the two closely-linked 
arms of the innate immune response: virus-induced IFN and inflammatory responses.  
PRR receptor knockout mice provided a good model for studying the roles of TLR3 and 
MDA5 in the innate immune response. However, as these receptor proteins reside at a 
proximal point in the innate immune signaling cascade, their absence will inevitably 
affect both IFN and inflammatory responses. Even the IKK-ε knockout could have 
complex effects.  To truly determine the specific role of RV-induced IFN production in 
the airway response, we could employ IFN α/β receptor knockout mice whose IFN 
responses are completely deficient, yet maintain intact inflammatory signaling. At first 
blush, one might expect these mice to have an increased inflammatory response due to an 
increase in viral load. However, given the modest pathogenicity of this virus and the 
small amount of viral replication which occurs in these mice (and, in particular, allergen-
sensitized and -challenged mice), we speculate that the inflammatory response in IFN 
receptor knockout mice could be unchanged, depending on the strength of infection.  
Virus and immune invasion strategies 
In our studies we have focused on the host response to viral infection.  However, 
many viruses have evolved the ability to either suppress the host immune system at 
various points along the antiviral signaling pathways. Hepatitis B and C virus have been 
shown to interfere with IFN-α/β defenses by down-regulating IPS-1 and inhibiting the 
activation of transcription factors IRF3 and NF-κB, respectively (32, 36-37). 
Paramyxoviruses can block the production of IFN-β by binding to MDA5 (38). Similarly, 
influenza A virus can inhibit IRF3 activation by binding to RIG-I (39). Picornavirus has 
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been shown to cleave RIG-I and MDA5 in vitro via the virus 3C protease and the 
caspase/proteasome pathways, respectively (40-41). RV1A has been shown to evade IFN 
responses by cleaving IPS-1 (42). However, most of these studies were conducted in 
susceptible cell lines such as HeLa cells, and none were conducted in airway epithelial 
cells. In our studies, we observed the cleavage product of MDA5 in BEAS-2B cells after 
RV infection; however, the degree of inhibition of the IFN response was negligible. 
Inhibition of the IFN response did not occur in our in vivo studies either. The virus-
induced inhibitory effect may be specific to cell type and affected by dose of virus used. 
The significance of the cleaved product of MDA5 after RV infection could be explored 
further in future.  
 The role of apoptosis in the response to RV infection is not clear. It has been 
argued that the early induction of apoptosis in infected cells increases the release of viral 
particles (43). On the other hand, others have suggested that apoptosis protects against 
viral infection by reducing viral release (44). In our studies, we did not specifically 
evaluate RV-induced apoptotic events. Deszcz and colleagues showed that RV infection 
could induce typical apoptotic morphological alterations in both Hela and 16HBE14o- 
immortalized human bronchial epithelial cells (43). Bronchial epithelial cells of asthmatic 
humans showed an impaired apoptotic response to HRV infection (19). On the other hand, 
relative to other viruses such as RSV or influenza, RV-infected cells show minimal 
cytopathic effects. In fact, studies from our group have shown that infection of polarized 
airway epithelial cell cultures with RV for 24 hours causes a significant decrease in tight 
junction resistance without causing cell death or apoptosis (45).  
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Physiological Relevance and Significance 
 RV accounts for most virus-induced asthma exacerbations, although the precise 
mechanisms are not well understood (1). In the studies for this thesis, we focused on the 
role of PRRs in the innate immune response after RV infection in airway epithelium. Our 
studies using a mouse model indicate that TLR3 and MDA5 mediate increased pro-
inflammatory responses and result in airway hyper-responsiveness in control mice 
compared to the knockout mice after RV infection. The same result is observed in OVA-
sensitized and -challenged mice. Therefore, while the presence of MDA5 provides a 
strong IFN response to clear invading viruses, both MDA5 and TLR3 cause increased 
inflammation in the infected lungs. These results are provocative. Is this inflammation 
necessary? Does the inflammation provide some benefit to the host?  
 Our data suggest that the severity of airway disease is determined mostly by the 
degree of inflammation caused by infection; therefore, we can say with some confidence 
that, in mice, the increased inflammation generated by a weakly pathogenic virus, such as 
RV, is harmful to the host. In the OVA-sensitized and -challenged model, we found equal 
viral clearance ability between control and MDA5-/- mice, suggesting that the degree of 
inflammation generated by allergic sensitization and challenge is more than necessary to 
clear viral infection, even in the absence of MDA5. Therefore, MDA5 and TLR3 
antagonists or inhibitors may provide potential therapeutic strategies for RV-induced 
airway diseases, and more importantly, asthma exacerbations. Alternatively, a second 
approach might be to infect airway epithelial cells with RV and screen chemical libraries 
for compounds which block the inflammatory response. These strategies, which focus on 
121 
 
the host response to virus rather than the virus itself, would represent a new approach to 
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